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ABSTRACT 
Toxicity is one of the main causes of failure during drug discovery, and of withdrawal once 
drugs reached the market. Prediction of potential toxicities in the early stage of drug 
development has thus become of great interest to reduce such costly failures. Since toxicity 
results from chemical perturbation of biological systems, we combined biological and 
chemical strategies to help understand and ultimately predict drug toxicities.  
First, we proposed a systematic strategy to predict and understand the mechanistic 
interpretation of drug toxicities based on chemical fragments. Fragments frequently found in 
chemicals with certain toxicities were defined as structural alerts for use in prediction. Some 
of the predictions were supported with mechanistic interpretation by integrating fragment-
chemical, chemical-protein, protein-protein interactions and gene expression data. 
Next, we systematically deciphered the mechanisms of drug actions and toxicities by 
analyzing the associations of drugs’ chemical features, biological features and their gene 
expression profiles from the TG-GATEs database. We found that in vivo (rat liver) and in 
vitro (rat hepatocyte) gene expression patterns were poorly overlapped and gene expression 
responses in different species (rat and human) and different tissues (liver and kidney) varied 
widely.  
Eventually, for further understanding of individual differences in drug responses, we 
reviewed how genetic polymorphisms influence the individual's susceptibility to drug toxicity 
by deriving chemical-protein interactions and SNP variations from Mechismo database. Such 
a study is also essential for personalized medicine. 
Overall, this study showed that, integrating chemical and biological in addition to genetic 
data can help assess and predict drug toxicity at system and population levels. 
Keywords: mechanism of drug-action, toxicogenomics, biological features, chemical 
features, 1000 Genomes 
 
 
 
  
  
v 
ZUSAMMENFASSUNG 
Toxizitäten von Arzneimitteln sind eine der Hauptursachen des Scheiterns während des 
Wirkstoff-Entdeckungsprozesses - und der Vom-Markt-Nahme, sollten diese bereits den 
Markt erreicht haben. Daher ist die Vorhersage potentieller Toxizitäten im frühen Stadium 
der Arzneimittelentwicklung von großem Interesse geworden, um diesen langen und teuren 
Prozess zu verbessern. Da Toxizitäten aus der Störung biologischer Systeme durch 
Chemikalien resultieren, kombinierten wir biologische und chemische Strategien, um 
vollständige Vorhersagemodelle für Arzneimitteltoxizitäten bereitzustellen. 
Zuerst haben wir eine systematische Strategie vorgeschlagen, um die mechanistische 
Interpretation von Wirkstofftoxizitäten auf der Basis chemischer Fragmente vorherzusagen 
und zu verstehen. Fragmente, die in hohem Maße mit bestimmten Toxizitäten 
zusammenhängen, wurden als Strukturalarmhinweise für die Verwendung in der 
Toxizitätsvorhersage definiert. Einige der Vorhersagen wurden mittels mechanistischer 
Interpretation durch Integration von Fragment-Chemie-, Chemie-Protein-, Protein-Protein- 
Interaktionen und Genexpressionsdaten unterstützt. 
Als nächstes haben wir systematisch die Mechanismen von Arzneimittelwirkungen und - 
toxizitäten durch Analyse der Assoziationen zwischen chemischen Merkmalen und 
biologischen Merkmalen von Arzneimitteln und ihren Genexpressionsprofilen aus der TG- 
GATE-Datenbank entschlüsselt.  In der Zwischenzeit fanden wir, dass sich in vivo 
(Rattenleber) und in vitro (Rattenhepatozyten) Genexpressionsmuster nur selten ähneln und - 
reaktionen bei verschiedenen Spezies (Ratte und Mensch), verschiedenen Geweben (Leber 
und Niere) weit variieren. 
Zum besseren Verständnis der individuellen Unterschiede in den Medikamentenreaktionen 
untersuchten  wir,   wie  genetische  Polymorphismen  die  Anfälligkeit   des   Individuums 
gegenüber der Wirkstofftoxizität beeinflussen, indem wir chemische Protein-Interaktionen 
und SNP-Variationen aus der Mechismo-Datenbank abgeleitet haben. Eine solche Studie ist 
auch wichtig für die personalisierte Medizin. 
Insgesamt zeigte diese Studie, dass die Integration von chemischen Merkmalen (z. B. 
chemische Fragmente, chemische Struktur), biologische Merkmale - einschließlich 
Genexpression und genetische Daten - die Toxizität des Wirkstoffs auf System- und 
Populationsniveau einschätzen und voraussagen können. 
 Schlüsselwörter: Mechanismus der Arzneimittelwirkung, Toxikogenomik, biologische 
Merkmale, chemische Eigenschaften, 1000 Genome 
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CHAPTER I: Introduction 
Despite overall dramatic increase in pharmaceutical R&D spending over the past few 
decades, relatively few drugs reached the market due to high failure rates at the clinical and 
pre-clinical testing stages (Kaitin, 2010). A major cause of these failures is toxicity (Paul et 
al., 2010). According to reports, only 8% of drug candidates in clinical trials entered the 
market, and around 20% of failures in the late drug discovery process were caused by the 
presence of toxicities (Muster et al., 2008). A small fraction of drugs were prohibited by 
regulatory agencies or withdrawn later after launching to the market due to the toxicity 
issues (e.g., adverse drug reactions, drug side effects) (Siramshetty et al., 2016).  
Despite the clinical impacts of drug toxicity, methods for monitoring them remain limited. 
Vast numbers of animals are used for testing toxicity in the pharmaceutical and cosmetic 
industry every year. Nevertheless, in line with the 3Rs (Replacement, Reduction and 
Refinement of animal testing) principle promoted by EPAA, alternative methods, such as in 
vitro arrays and in silico models have been prevalently established and optimized. In vitro 
methods test toxicity by measuring the biochemical and cellular assays of chemical 
compounds, but experimental examinations are more challenging, in terms of efficiency 
and operating cost (Bowes et al., 2012). Thus, in silico predictions of potential toxicities in 
the early stages of drug development have become an efficient way of improving this long 
and expensive process. Machine learning algorithms are used in much of our daily life in 
everything from smartphone apps (e.g., voice recognition, online transaction) to self-
driving cars. Drug discovery studies have profited from these developments and also the 
many improvements in cheminformatics and bioinformatics (Ekins, 2016). 
Chemoinformatics and bioinformatics have brought about beneficial insights particularly 
via analysis of high throughput data from drug discovery. The following chapter sections 
introduce the current roles of in silico methods in toxicity testing and propose a framework 
for a combined biological-chemical approach that can improve the efficiency and reduce 
cost for toxicity prediction. 
1.1 Cheminformatics-based predictions in toxicology 
Cheminformatics-based predictions broadly rely on structure-based methods. The principle 
is to link chemical structures (represented by molecular descriptors) to their activities or 
properties (e.g., toxicity endpoints). The methods broadly can be classified into QSAR 
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(quantitative structure-activity relationship) and expert system approaches (Valerio, 2009). 
More precisely, QSAR modeling establishes quantitative relationships between chemical 
structures and activities via statistical functions (activity = f(structural properties), where 
activity might be the value of IC50) (Valerio, 2009). Structural properties are represented by 
chemical descriptors, ranging from physicochemical properties (e.g., molecular weight, 
hydrophobicity, and charges), chemical fragments (e.g., structural alerts), molecular 
fingerprints (e.g., MACCS keys) to quantum mathematics (e.g., orbital energies) 
(Todeschini and Consonni, 2000). To set up this mathematical function, a set of chemical 
descriptors are calculated for the group of chemical compounds with known activities (e.g., 
IC50). Descriptors are then weighted according to their correlation with activity values, thus 
defining the most accurate function to predict activity based on chemical structure. 
With the evolution of chemical descriptors, a wide range of algorithms have been applied to 
QSAR, including Multiple Linear Regression (MLR), k-Nearest Neighbors (KNN), 
Principal Component Analysis (PCA), and Support Vector Machines (SVM) 
(Nantasenamat et al., 2010). Recently, within the framework of Big Data methods, a novel 
algorithm - Deep Neural Network (DNN) - has been developed and was shown to 
outperform all the other methods participated in the Tox21 Data Challenge (Unterthiner et 
al., 2016).  
In contrast to the above algorithms, expert systems attempt to capture human expert 
knowledge related to structure features and their relationship to toxicity and mechanism. 
Methods define rules that represent more interpretable means to label compounds and 
relating them to potential toxicities. These structure features are known as structural alerts 
(SAs) or toxicophores. For example, some substructures are used as mutagenicity alerts in 
the expert systems DEREK (Ridings et al., 1996) and Toxtree 2.1.0 (Benigni and Bossa, 
2008). Overall, chemical structure-based models can be defined quantitatively (e.g., QSAR 
defines mathematical function) and qualitatively (e.g., expert systems define toxicity by the 
presence of structural alerts), which enables chemists or pharmacists to exploit QSAR 
models with higher accuracy to filter drug candidates and regulation agencies to check new 
drugs for interpretable mechanisms of toxicity.  
Most QSAR predictors don not fully capture complicated biological processes. This is 
sometimes due to defects in data selection, modeling approaches, and validation. There 
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have been many attempts including training data set curation, descriptor selection, 
appropriate modeling algorithms development, and validation strengthen have been made to 
improve the QSAR modeling.  
In the reality, the complex relationship between chemical structures and toxicities is likely 
never to be fully understood without realistic models of organismal biology. Simple models 
do not capture the complexity of ADME (absorption, distribution, metabolism, and 
excretion) process in pharmacokinetics (Hansch et al., 2004) and are also woefully 
inadequate to capture the even greater complexity and diversity of toxic responses. QSAR 
is nevertheless useful for predicting specific and direct chemical-activated toxicities (e.g., 
mutagenicity that could be predicted by the interactions of chemicals and DNA) even if it is 
less successful at predicting toxicities arising from chemical-perturbed biological pathways 
involving proteins targeted by chemicals (e.g., carcinogenicity) (Ashby and Tennant, 1991; 
Benigni and Bossa, 2008). Human rule-based expert systems also have their limitations, 
because the rules derived from knowledge of human experts are incomplete and biased, and 
updating the system is difficult, requiring extensive literature to be carefully reviewed. 
These limitations make accurate and efficient toxicity predictors challenging. 
1.2 Bioinformatics-based predictions in toxicology 
The increasing availability (and decreasing cost) of high-throughput chemical screens (HTS) 
and high-throughput ‘omics’ tools (transcriptomics, proteomics, etc.) has been paralleled by 
the development of associated computational bioinformatics tools and expertise to help 
unravel mechanisms of diseases and drug toxicity. Adding novel data streams to models has 
been proposed to help alleviate the shortcomings mentioned above.  
Omics studies provide large datasets for each toxic endpoint, and thus give the system view 
of toxicity, involving all the molecular players (e.g., DNA, RNA, proteins, and metabolites) 
instead of considering each of them separately. When a biological system is perturbed by an 
exogenous agent (e.g., a drug), the expression of some genes may be dysregulated 
(transcriptomics), leading to the dysfunctions of proteins (proteomics) and metabolites 
(metabolomics) (Figure 1.1). Toxicogenomics was developed to harness the collective 
technologies of genomics, proteomics and metabolomics, to study the adverse effects of 
toxic substances on biological system and ultimately to improve efficiency and safety 
through a better understanding of mechanism (Hamadeh et al., 2002).  
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Figure 1.1 Illustration of gene expression changes elicited by a drug and its metabolic pathway. The drug 
(green hexagon) binds to a receptor (magenta ellipse) on the cell surface and a series of signaling events are 
triggered, resulting in the expression of drug metabolizing genes, such as phase I modification enzymes (e.g., 
CYP1A1 and 1B1) and phase II conjugation enzymes (e.g., GST and UGT1A), leading to activation, 
detoxification and excretion. Meanwhile, the toxic features of the drug cause gene expression changes (e.g., 
red ellipses are up-regulated and blue are down-regulated).  
Transcriptomics measures the genome-wide mRNA expression (Barh et al., 2013) to 
provide gene expression changes involved in pathways or networks that might lead to toxic 
effects. DNA microarrays are one of the most common techniques. These measure tens of 
thousands of gene expression values by assessing the degree to which a sample of RNA or 
DNA hybridizes to a chip containing DNA probes (usually from a whole genome). The 
utility of gene expression profiles of toxicant responses is based on the presumption that 
compounds with similar toxicity mechanisms will give similar transcriptional changes 
(Waring et al., 2001). There is now a vast literature of microarrays applied to toxicology. 
For example, Huang et al., exploited cDNA microarrays to examine the expression 
alterations of genes involved in pathways of cell apoptosis, calcium homeostasis, and 
proposed a putative cisplatin-induced nephrotoxicity mechanism (Huang et al., 2001). 
Microarray studies are typically limited by the complexity of understanding gene 
expression changes and how they related to toxicity, and the oft-cited problem that 
alterations at the transcriptomic level do no always reflect protein expression (Barh et al., 
2013). 
Proteomics is the systematic, normally high-throughput study of proteins in a biological 
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context (e.g. cell, tissue, organ, disease, etc.). One typically measures expression, 
interactions with other molecules or aspects of function (e.g. post-translational 
modifications). Proteomics experiments are sometimes used to complement toxicogenomics, 
to help assess biological response by capturing altered proteins associated with the toxicant 
exposure. Key technologies include 2D gel electrophoresis combined with mass 
spectrometry analysis for protein separation (Shruthi et al., 2016), multi-dimensional liquid 
chromatography/mass spectrometry for protein characterization (Shruthi et al., 2016), and 
fluorescence resonance energy transfer for protein-protein interactions detection (Barh et al., 
2013). For example, Linge and coworkers used 2D gel electrophoresis to define fourteen 
altered proteins as novel biomarkers in melanoma patients (Linge et al., 2012). While 
several useful protein biomarkers for particular toxic responses have been identified (e.g. 
kidney injury molecule-1, Kim1, for nephrotoxicity) (Ichimura et al., 2008), there are still 
many pathologies lacking any clear biomarker. Biomarkers, once identified, can both aid 
the prediction of toxicities for new compounds and also help to understand the underlying 
mechanisms that drive particular pathophysiologies.  
Metabonomics is the study of the metabolic response of a living system to external stimuli 
or genetic perturbation. Within toxicology, the hypothesis is that toxicant-induced 
pathologies lead to modifications of metabolic pathways via changes in the concentrations 
of metabolites. Such changes can be determined by the changes of flux distribution 
compared with that of the steady state (Carbonell et al., 2017). Common techniques include 
gas chromatography mass spectrometry (GC-MS), liquid chromatography mass 
spectrometry (LC-MS), and nuclear magnetic resonance (NMR) spectroscopy, all of which 
measure these concentrations (Wishart, 2016). One well-known application of 
metabonomics in toxicity prediction was performed within the Consortium for 
Metabonomic Toxicity (COMET) where metabonomics was used to build an expert system 
to predict the drug-like-induced liver and kidney toxicities in rodents (Lindon et al., 2005). 
More recently, even smartphone streamlined metabonomics apps for chemical toxicity 
assessment have also been presented (Kwon et al., 2014). 
Overall, computational modeling, in the context of toxicology, has to some extent 
disregarded detailed information about chemical compounds, while cheminformatics-based 
approaches typically neglect biological mechanism. In the era of Big Data, masses of 
toxicity data, consisting of both chemical and biological attributes, argues for an integration 
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of these two approaches. Clearly, toxicities of drugs and the associated mechanisms should 
be studied from the viewpoint of the whole system (i.e., systems toxicology). 
1.3 Integrated chemical and biological modeling-based predictions in 
toxicology 
From the viewpoint of systems biology, drug action can be seen as the perturbation of the 
biological systems, which involves drugs interacting with both desired targets and 
undesired proteins (i.e. off-target interactions), as well as associated protein-protein 
interactions, metabolic pathways and signaling pathways, all of which produce intended 
and unintended effects (Keiser et al., 2009). It is known that most drugs bind to multiple 
target proteins with a wide range of affinities, which together is responsible for both desired 
drug actions and toxicity (Walker et al., 1999). For example, a cardiovascular agent, 
propranolol, which targets β-adrenoceptors (i.e. a β-blocker), was observed to interact with 
receptors in secondary organ systems, leading to bronchoconstriction in asthma (Ahmed 
and Branley, 2009), characterized as an exaggerated on-target effect. Another example is 
the anti-obesity medication, fenfluramine, which induced valvular heart disease via 
activation of 5-Hydroxytryptamine receptor 2B (5-HT2B), what led to its withdrawal from 
the market (off-target effects) (Roth, 2007).  
Overall, drug toxicity can be considered as how drugs via molecular interactions trigger 
adverse outcomes across different levels of human organization (cellular, tissue, organ, 
system) over time and as a function of dose (Figure 1.2). Unfortunately, only a few 
relationships between drug targets and toxicity endpoints have been well established, with 
most mechanisms remaining unknown (Vedani et al., 2012). Recent advances in big data 
acquisition, complemented by new experimental tools make systems toxicology, via the 
simultaneous combination of biological and chemical information more feasible.  
Carbonell et al. have developed a systems-wide protocol for modeling organ-specific 
toxicity. Models integrate gene expression data, metabolic pathway signatures and 
hepatotoxicity observations in primary human hepatocytes treated by 77 chemical 
compounds. Cheminformatics models, based solely on chemical structure features, found 
some relationships between chemical features and toxicities. The integration with gene-
expression data also provided general mechanistic hypotheses for hepatotoxicity (Carbonell 
et al., 2017). 
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Perualila-Tan and colleagues developed a joint model by integrating transcriptomic, 
phenotypic and chemical structure data. The model aimed to predict the impact of each 
chemical structure feature on gene expression and toxicity pIC50 (–log IC50) values. Two 
case studies were used to test the applicability of the model in drug discovery. The EGFR 
(epidermal growth factor receptor) dataset contained 35 compounds and expression data for 
3595 genes, and the ROS1 (reactive oxygen species) dataset contained 89 ROS inhibitors 
with 312 unique substructures. After pooling individual predictions from the compound-
gene expression and compound-substructure models into a final predicted value, the joint 
model gave an integrated view of how chemical substructures were associated with 
toxicities. For example, the model revealed that the higher expression of the genes TXNRD1 
and FNIP1 (ROS1 inhibition and cancer related genes) were linked to the presence of the 
particular substructure FF-2086493472 (Perualila-Tan et al., 2016). 
A relative new conceptual construct for toxicity assessment hosted by the Organisation for 
Economic Co-operation and Development (OECD) are adverse outcome pathways (AOPs), 
which capture interactions between chemical initiating events and adverse outcomes 
through curated biological (Ankley et al., 2010). This concept has been used, for example, 
to aid environmental toxicity prediction through the use of well-understood biological 
pathways and genomic data, which has highlighted mechanisms downstream of the initial 
chemical-induced key events. Algorithms analyzing data in the AOP framework are still 
somewhat limited. Recently, Antczak et al. built a multistep modeling method, which 
combines traditional QSAR modeling, gene expression and toxicity information from 
Daphnia magna. They described a strategy for defining putative AOPs via the integration 
of chemical structures with mechanistic insights from genomic data, and observed adverse 
outcomes (Antczak et al., 2015). 
Stem cells have also recently played important roles in toxicity prediction. For example, 
Yamane and co-workers first constructed a predictive SVM model using qRT-PCR data 
from human embryonic stem cells (hESC) treated by twenty compounds. After adding edge 
weights for a gene-gene interaction network to the model, prediction accuracy for 
neurotoxicity, genotoxic and non-genotoxic carcinogens reached to at least 97.5%. 
Moreover, this study used only undifferentiated hESCs, representing the potential to predict 
late-onset toxicity, and the toxicities observed during embryonic development (Yamane et 
al., 2016). 
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An et al. (An et al., 2016) proposed a predictive model for assessing adverse drug reactions 
within liver and kidney. They trained 210 chemical features extracted from 108 drugs in 
Japanese Toxicogenomics Project database (Uehara et al., 2010) by four models (ANN, 
kNN, LDA, and SVM) to predict toxicity. Compared to other models predicting toxicity 
within single organs, their multiple organ models (i.e. considering organs other than the 
target) provided more comprehensive knowledge of drug-induced adverse effect 
mechanisms in humans (An et al., 2016). 
1.4 Predictive toxicology at human population level 
Accessing individual differences in drug toxicity is a new challenge for toxicology and 
personalized medicine. Accordingly, pharmacogenomics has emerged to help uncover how 
human genetic variation affects drug efficacy and toxicity and provide more precise 
prescription to patients. Genetic variations, including common genetic variants, mostly are 
single-nucleotide polymorphisms or SNPs, and rare variants in genes that participate in 
drug pharmacodynamics or pharmacokinetics play a role in individual variability (Roses, 
2000). SNPs in genes encoding drug targets, drug transporters, drug-metabolizing enzymes 
could impact patients’ sensitivity to a drug (McLeod and Evans, 2001). So far, many efforts 
have been put to identify associations of genetic variations and drug-induced phenotypes. 
Genome-wide association studies (GWAS) is one of the most popular methods for this 
purpose. For example, GWAS has successfully identified variants located on VKORC1 
(vitamin K epoxide reductase complex subunit 1), CYP2C9, and CYP4F2, the targets of the 
anti-coagulant warfarin. Some variations in VKORC1 are involved with resistance to 
warfarin, and others affect warfarin dosage within the normal range prescribed. Variations 
in CYP2C9 and CYP4F2 are associated with the speed of metabolizing warfarin. In poor 
metabolizers (slow-processing), warfarin blood concentration can rise, leading to toxicity 
(Takeuchi et al., 2009). With the help of GWAS, a great number of SNPs related 
phenotypes have been identified. Recently, technological advances in sequences mean that 
exome or even whole genome sequences are more commonplace (The 1000 Genomes 
Project Consortium, 2015; Lek et al., 2016). The 1000 Genomes (The 1000 Genomes 
Project Consortium, 2015) and ExAC projects (Lek et al., 2016), which sequenced or 
collected genomes of thousands of people, provide information to help fine-map 
pharmacodynamics and pharmacokinetics-associated loci. 
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Personalized or precision medicine aims to use the sequences of an individual’s genes to 
make more rational treatment and dose suggestions for better efficacy and reduced toxicity. 
For example, Roche has developed the AmpliChip to detect the cytochrome P450 gene 
family variants that might affect drug efficacy or detoxification. 35% of the general 
population has found to carry abnormal CYP2D6 alleles, making them either poor or ultra 
metabolizers. AmpliChip can detect up to 33 CYP2D6 alleles to aid treatment decisions 
(Rebsamen et al., 2009). Computational phenotyping facilitates a fast development of 
quantitative models for individual’s drug toxicity risk. For instance, integrating preclinical 
biological experiments, clinical, human imaging and drug information, allowed the 
prediction of clinical responses for certain drugs (Geerts et al., 2015). Overall, personalized 
medicine is clearly an emerging theme in healthcare, and a wealth of novel discoveries 
from this field will ultimately improve risk assessment in medicine (Ingelman-Sundberg, 
2015). 
 
Figure 1.2 Scheme of drug toxicity prediction in complex biological systems. Drug chemical structures, 
targets, SNPs (target or other genes), the associated biological networks, metabolic pathways, tissues/organs 
influenced by the drug are all keys to understanding and predicting biological responses. 
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1.5 Dissertation outline 
Technologies such as gene sequencing, transcriptomic profiling, proteomics, metabolomics, 
and pre-clinical or clinical data related to single cells, organs, or patient populations provide 
the Big Data relevant to systems pharmacology and toxicology, which in principle should 
allow better predictions of drug action and adverse responses. Only when all these data are 
integrated can researchers and clinicians develop models or concepts to better predict 
outcomes. 
This dissertation presents systems approaches to addressing some of the above problems 
(Figure 1.2). Chapter II presents a chemical fragment/substructure-based approach to 
toxicity prediction exploiting machine learning (support vector machines (SVM) and sparse 
canonical correlation analysis (SCCA)) methods. Such fragment-based approaches are 
well-established for the development of novel lead compounds (Schuffenhauer et al., 2005). 
However, they can also be employed to identify fragments indicative of toxicities (Siegel 
and Vieth, 2007). We propose a predictive toxicity protocol based on chemical structures. 
We focus initially on the systematic derivation of chemical fragments associated with 
particular toxicities using an overall literature basis and avoiding any bias or limitations 
introduced by expert curation. Some of the enriched fragments for specific toxicities are 
potential structural alerts for future predictions on new drugs. We also provide mechanistic 
interpretation for some of the fragments by integrating chemical-protein interactions, 
protein-protein interactions and gene expression data.  
Chapter III generally explores the mechanisms of predictive toxicity. Predictive systems are 
generally more accepted if they provide descriptions of mechanism (e.g., drug metabolizing 
pathways) that underlie the biological properties of the molecule. The response of a 
biological system to a toxicant that afterwards causes pathology in certain organs can then 
be examined as changes in the expression of genes, proteins synthesis, and metabolism. Of 
these changes, the expression of genes is the most sensitive and readily accessible 
experimentally. Therefore, toxicogenomics, which measures gene expression changes 
caused by a toxin in a specific cell, tissue or organ, has become one of the most powerful 
strategies. We employ the Toxicity Evaluation System developed by the TGP in Japan 
(Uehara et al., 2010), which provides comprehensive toxicogenomics data for hundreds of 
compounds to uncover relationships between changes in gene expression and toxicity data. 
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Resources like this can help to identify candidate gene/protein biomarkers of toxicity. Such 
datasets also permit us to test hypotheses such as whether or not in vitro bioassays can be 
utilized to predict in vivo responses. 
Chapter IV attempts to study the underlying mechanisms of drug response differences 
among individuals and populations. Besides chemical and bioassay results, the recent 
availability of data for healthy individuals provides new possibilities to study drug effects 
in human populations. The Mechismo tool (developed in our group) provides potential 
mechanisms for how proteins interact with other molecules (i.e., proteins, chemical 
compounds, nucleotides) and how any changes/variations might affect these interactions 
and consequently an entire biological system (Betts et al., 2015). In this chapter, we use 
Mechismo to study data from the 1000 Genomes Project to investigate which genetic 
variations might impact drug response differences among individuals and subpopulations.  
The concluding chapter summarizes the findings from the entire thesis and discusses their 
contributions towards predictive toxicology and personalized medicine. 

13 
CHAPTER II: Chemical fragments as foundations for 
understanding the toxic effects of chemicals on biological 
systems 
2.1 Abstract 
The building blocks (fragments) of chemicals can sometimes be associated with particular 
biological effects of the chemical as a whole (e.g., metabolism, disease, pharmacological 
actions, toxicity). In this chapter, we present a systematic strategy to predict and 
understand the mechanistic interpretation of chemical toxicities based on chemical 
fragments.  
To identify toxicity structural alerts (SAs), we derived 93 902 chemical compounds with 
structures and MeSH (Medical Subject Headings) terms from PubChem (Bolton et al., 
2008), and their fragments from the ZINC database (Irwin and Shoichet, 2005). We 
classified compounds into different toxic (or non-toxic) classes according to information 
extracted from the literature, and performed statistical analyses to identify chemical 
fragments enriched particular classes (as potential structural alerts). 
Hundreds of fragments strongly related to specific toxicities were identified, which might 
be regarded as structural alerts for using in toxicity prediction. For validation, we 
performed toxicity predictions with support vector machines (SVM) and sparse canonical 
correlation analysis (SCCA) for 263 withdrawn drugs. Some predictions were supported 
by mechanistic explanations obtained by integrating fragment-chemical, chemical-protein, 
protein-protein interactions and gene expression data. Our findings might ultimately help 
understand toxicities of unknown chemicals and their potential mechanisms to aid drug 
development. 
2.2 Introduction 
Several in silico methods for predicting toxicities have been proposed previously. Most 
approaches relate particular chemical fragments to toxicity by statistical analysis, meaning 
that the fragment is significantly enriched in toxic compounds compared to others (Schnur 
et al., 2006). To date, a number of structural alerts (toxic fragments/ toxicophores that are 
associated with toxicity) (Ashby and Tennant, 1988)) have been defined for several toxic 
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endpoints (Liu et al., 2015). For example, Ashby and Tennant identified a set of structural 
alerts correlated with the modification of DNA based on the data from both in vivo 
carcinogenicity and in vitro mutagenicity (Ashby and Tennant, 1991). Benigni and Bossa 
reported 31 classes of structural alerts for carcinogenicity and mutagenicity with 
corresponding mechanisms of action (Benigni and Bossa, 2011), which has been 
implemented as prediction rules into Toxtree 2.1.0 (Benigni and Bossa, 2008). Expert 
systems are either developed manually or statistically by extracting expert knowledge, to 
predict the molecular toxicity based on the presence or absence of toxic fragments in their 
chemical structure. The program DEREK (from Lhasa Limited; 
http://www.lhasalimited.org) is an example of rule-based expert system where most 
general endpoints (e.g. reproductive toxicity and genotoxicity) are directly indicated by 
toxic fragments like phthalate, or nitrobenzene, if they have been detected in the examined 
molecules (Ridings et al., 1996). Another example is HazardExpert from CompuDrug, 
where the toxicity prediction is based on the list of known toxic fragments collected from 
the U.S. Environmental Protection Agency (Brink and Walker, 1987). Similarly, CASE, 
probably the first automated expert system, automatically recognizes structural alerts in 
new chemicals (Klopman, 1984). Other programs such as PASS (Poroikov et al., 2000), 
Cat-SAR (Cunningham et al., 2008), and LAZAR (Helma et al., 2004) also identify 
structural alerts indicative of toxicities. Rule-based systems have some limitations 
(Lepailleur et al., 2013; Liu et al., 2015), specifically: i) the number of structural alerts is 
limited for general toxic endpoints (e.g., hepatotoxicity) ii) they require extensive man-
power to harvest results from the literature to remain up to date, and iii) the opinions of the 
experts can lead to biases and potentially inaccurate results i.e., non-toxic compounds 
containing a structural alert might be predicted to be toxic. 
The development of data mining tools enables one to detect large-scale novel structural 
alerts beyond the limits of human perception. Commonly used machine learning 
algorithms for this purpose include multiple linear regression (MLR), partial least squares 
(PLS), support vector machines (SVM) and k-nearest neighbors (k-NN). For example, in a 
study from Zhang et al., liver toxicities of 1317 compounds were predicted using machine 
learning methods (e.g., SVM, k-NN, Random Forest, RF) based on a substructure pattern 
recognition method (Zhang et al., 2016). The best model (SVM) showed much higher 
predictive accuracies for the training set, test set and an external validation set compared 
to previous QSAR methods. Moreover, six structural alerts related to the mechanism of 
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drug-induced liver injury (DILI) were identified, which could be utilized for irradiating 
chemicals that might induce DILI. Mazzatorta et al. reported the correlation of chemical 
substructures from over 400 compounds and the chronic toxicity by a predictive model 
built on MLR and PLS methods. The model predicted that the chronic toxicity is caused 
by compounds containing particular chemical moieties (Mazzatorta et al., 2008). Pauwels 
et al. proposed sparse canonical correlation analysis (SCCA) model to predict potential 
side-effects of drugs in large molecular database based on their chemical fragments. The 
unique feature of this model is the capacity to extract the associations of side-effects of 
drugs and the emergence of structural alerts (Pauwels et al., 2011). The software SARpy 
automatically generated and selected chemical fragment structural alerts by analyzing the 
correlation between the frequency of each chemical fragment and the experimental 
activity of the chemicals (Ferrari et al., 2013).  
Predictive systems are more acceptable if they provide a description mechanism, i.e., the 
interactions between the molecule and target proteins or systems that lead to its ultimate 
biological effects. The response of a biological system to a toxicant that afterwards causes 
pathology in certain organs can be examined as changes in the expression of genes, 
proteins synthesis or metabolism. Of these, gene expression is the easiest to measure and 
interpret. For example, Low et al. developed hybrid models combining chemical and 
toxicogenomics descriptors for 127 drugs from the Japanese Toxicogenomics Project 
(Uehara et al., 2010) using classification methods (k-NN, SVM, RF, and distance 
weighted discrimination, DWD). Besides identifying and verifying chemical structural 
alerts for hepatotoxicity by HiT QSAR (Kuz'min et al., 2008) and XCHEM (Sedykh and 
Klopman, 2006), the transcripts predicted related to DILI mechanisms were also predicted 
(Low et al., 2011). Hewitt et al. clustered 951 diverse compounds into a few structurally 
clusters by molecular structure similarity and identified sixteen structural alerts associated 
with human hepatotoxicity, which were supported by mechanistic insights by gene 
expression (Hewitt et al., 2013). Antczak et al. proposed a system level strategy to define 
putative toxicity pathways by integrating chemical structure information with pathways 
defined by gene expression profiles induced by 26 chemicals, and their observed 
phenotypic effects (Antczak et al., 2015).  
An increasing number of databases are available to aid drug discovery by providing 
information on chemical fragments, chemical-protein interactions, protein-protein 
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interactions, toxic endpoints and gene expression. For example, the ZINC database stores 
162 261 (2013-11-05) “fragment-like” molecules that have molecular weight less than 250 
g/mol, LogP values between -2 and 3, fewer than three hydrogen-bond donors, fewer than 
six hydrogen-bond acceptors and fewer than three rotatable bonds (Irwin and Shoichet, 
2005). FragmentStore uses modified Lipinski rule-of-five criteria (Lipinski et al., 2001) to 
validate fragments for assembling compound libraries. The library contains more than 35 
000 fragments derived from more than 13 000 metabolites, 2 200 toxic compounds and 16 
000 drugs (Ahmed et al., 2011). 
There are also a wide range of toxicity databases capturing different measures of toxicity. 
The ToxCast program (Kleinstreuer et al., 2014) and Tox21 (Mahadevan et al., 2011) 
developed by the United States Environmental Protection Agency (US EPA) provide 
overall toxic effects for about 10 000 environmental chemicals and drugs. Non 
confidential regulatory submissions such as the European Chemicals Agency (ECHA) 
(http://echa.europa.eu/) and INCHEM (http://www.inchem.org/) also provide relevant data 
of toxic studies on compounds.  
In order to link the chemicals to proteins, interactions from a variety of databases of 
chemical-protein interactions are available, for example, experimental evidence 
interactions from protein data bank (PDB) (Gutmanas et al., 2014) and PDSP Ki databases 
(Roth et al., 2000), interactions from pathway databases KEGG (Kanehisa et al., 2012) 
and Reactome (Fabregat et al., 2016), and interactions from integrated database such as 
STITCH (Kuhn et al., 2014) which merge other databases. Resources that archive 
published protein-protein interactions are also available, such as Network Database (BIND) 
(Bader et al., 2003), Biological General Repository for Interaction Databases (BioGRID) 
(Chatr-aryamontri et al., 2015), the Database of Interacting Proteins (DIP) (Xenarios et al., 
2002), IntAct, Molecular Interaction database (MINT) (Orchard et al., 2014). All of these 
are merged in the Proteomics Standard Initiative Common Query Interface (PSICQUIC) 
(Aranda et al., 2011). 
Toxicogenomics datasets of gene expression (e.g. CMAP (build 02) 
(http://www.broad.mit.edu/cmap/) (Lamb et al., 2006), as discussed in the last chapter, 
also provide details on expression changes induced by toxicants.  
In this chapter, we propose a combined method to predict toxic endpoints. The method 
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exploits a combination of statistical analyses with machine learning algorithms (SVM and 
SCCA) to investigate the correlation between compound fragment with toxic endpoints 
derived from databases and the literature. We achieved good performance and high 
accuracy for predicting toxic endpoints of chemicals with proposed structural alerts. We 
also supplement prediction with putative mechanisms of toxicity, if possible, data on 
chemical-protein interactions (both on and off-targets), protein-protein interactions and 
gene expression datasets used to make the predictions.  
2.3 Methods 
2.3.1 Data preparation 
93 902 chemical compounds with MeSH terms and their structure files were downloaded 
from PubChem (2013) (Bolton et al., 2008), and chemicals with fewer than four non-
hydrogen atoms and more than 20 atoms were removed.  
The external validation set containing 258 known toxic compounds with annotated gene 
expression changes in toxicogenomics experiments was retrieved from ToxWiz 
(http://www.toxwiz.com/). 
263 withdrawn drugs as the test set to evaluate the interest of the models for predicting 
toxicities for uncharacterized drugs were collected from WITHDRAWN database 
(Siramshetty et al., 2016). 
The clean fragment-like subset of 162 261 molecules dated on November 05, 2013 was 
downloaded from ZINC (version 12) (Irwin and Shoichet, 2005) as the substructure 
dataset.  
All compounds were represented by SMILES strings, a widely used notation of encoding 
chemicals as ASCII strings (Weininger, 1988). Additional refinements including adding 
hydrogen to fulfill the valences of non-hydrogen atoms and neutralizing the charges were 
processed for all the chemical files with Open Babel 2.3.2 (O'Boyle et al., 2011). 
Conversions of files from .mol, .sdf chemical format to SMILES and the substructure 
searches were also implemented using Open Babel 2.3.2. 
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2.3.2 Extracting toxicity information 
A total of 20 toxicity categories were defined based on the pathology pathways in ToxWiz 
(http://www.toxwiz.com/). These categories include 1504 MeSH terms of toxicity 
endpoints from 20 systems: male reproductive system, development, digestive system 
(excluding hepatic), lymphatic system, endocrine system, sensory apparati, integumentary 
system (e.g. skin, hair), activity system (e.g. muscle, bone), connective and other tissues & 
cells, pan-systemic pathologies, hepatic system, urinary system, circulatory system, 
respiratory system, immune system, nervous system, reproductive system (general), other 
toxicity related clusters, female reproductive system. The most prevalent toxicities (in 
terms of numbers of compounds) are neurotoxicity, hepatotoxicity, cardiotoxicity and 
genotoxicity. 
Compound-toxicity relationships were generated by automatically identifying PubChem-
MeSH-PubMed links and crossing compounds with references containing the textual 
terms (e.g. hepatotoxicity, carcinogenicity, mutagenicity, developmental toxicity).  
2.3.3 Classifying fragments and dataset diversity 
An important aspect of the fragment-based toxicity prediction is to assess diversity within 
a set of compounds having a particular property. This is important to avoid highly similar 
compounds (i.e. those that are likely derived from one another) dominating the fragments 
groups. A Tanimoto similarity calculation, for fragment dataset, was performed by a 
method based on MolPrint 2D (Bender et al., 2004) to determine whether a fragment is 
structurally novel. The Tanimoto coefficient (TC) is defined as follows: 
𝑇(𝑎, 𝑏) =
ே௖
ே௔ା ே௕ିே௖
                                                                      (2.1) 
where Na and Nb are the number of bits set (denoting presence or absence of a particular 
fragment) for binary fingerprints of molecules A and B, respectively, and Nc is the set bits 
that A and B have in common. To estimate whether a dataset is structurally novel, an all-
by-all similarity matrix was calculated for these compounds. We defined compounds to be 
similar if the Tanimoto coefficient was 0.85 or above (Martin et al., 2002). We left single 
representatives for each group, and removed groups having fewer than four compounds.  
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2.3.4 Toxic fragments analysis 
In order to identify whether a specific fragment is more frequent in a toxic than a nontoxic 
class, the ratio of the observed/expected value was calculated. If a fragment was more 
frequently presented in a particular toxic class than the expected number, this fragment 
was determined to be toxic. The expected number of the presence of a fragment in a 
particular toxic class is defined as following:  
𝑒𝑥𝑝 =  
ே೑ೝೌ೒೘೐೙೟_೟೚೟ೌ೗ ∗ ே೟೚ೣ೔೎೔೟೤_೟೚೟ೌ೗
ே೟೚೟ೌ೗
                                               (2.2) 
Where Nfragment_total is the number of compounds containing the fragment; Ntoxicity_total is the 
number of compounds in each toxic class; and Ntotal is the total number of fragment-
chemical-toxicity pairs. The test of statistical significance for the observed/expected can 
be obtained in R fisher.test (Agresti, 2002). In this study we consider p < 0.05 is 
statistically significant. 
2.3.5 Prediction methods 
2.3.5.1 Support vector machines (SVM) 
Support vector machines (SVM) are a widely used technique for classification in 
bioinformatics and chemoinformatics (Guyon et al., 2002; Pauwels et al., 2011). The 
kernlab package in R (version 0.9-24) (Karatzoglou et al., 2004) was used in our study. 
We tested linear kernel and multiple nonlinear kernels; the Gaussian RBF kernel function 
was found to have the best performance. For a good generalization capacity of the 
classifier, two kernel parameters should be defined well, i.e. C and σ, where C is a cost 
factor that balances the trade-off between margin and training error and σ is a kernel 
parameter. 5-Fold cross-validation was applied to train nonlinear SVM(s) with various C 
values in the range of 2-10 to 215 and an automatically determined σ, and the combination 
of C and σ that generated the highest cross-validation accuracy was selected for training. 
The trained models were applied to the test set to predict whether a given compound is 
linked to toxicity endpoint or not. We constructed classifiers for each of the toxicity 
endpoints in our study. 
2.3.5.2 Sparse canonical correlation analysis (SCCA) 
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Canonical Correlation Analysis (CCA) makes it possible to find linear combinations of 
two sets (p fragments and q toxic effects) generated from n samples (compounds) with the 
highest correlations. CCA enables one to find linear combinations of all the variables in 
matrix X (p × n) that maximally correlate with linear combinations of all the variables in 
matrix Y (q × n). Considering two linear combinations as canonical variates α = Xu and β 
= Yv, with the weight vectors u' = (u1, ..., up) and v' = (v1, ..., vq). The optimal weight 
vectors are obtained by maximizing the canonical correlation coefficient between the 
variate pairs: 
𝜌 = 𝑐𝑜𝑟𝑟 (𝑢, 𝑣) =
௩ᇱ௒ᇱ௑௨
√௩ᇲ௒ᇲ௒௩√௨ᇱ௑ᇱ௑௨
                                                  (2.3) 
In regular CCA, the weight vectors u and v are not unique if p or q is large. In our study, 
we used Sparse CCA (SCCA) based on the method proposed by Pauwels et al. (Pauwels et 
al., 2011) for high-dimensional settings, where assuming that the columns of X and Y are 
uncorrelated, therefore, SCCA considers solving another form of CCA with the following 
optimization problem: 
𝑎𝑟𝑔𝑚𝑎𝑥
𝛼, 𝛽  𝛼′ ∑ 𝑋𝑌𝛽 subject to ‖𝛼‖
2
2
= 1, ‖𝛽‖2
2
= 1, ‖𝛼‖
1
≤ 𝑐1ඥ𝑝, ‖𝛽‖
1
≤ 𝑐2ඥ𝑞    (2.4) 
where ∑ XY is the covariance matrix of X and Y, and ‖. ‖
1
 is L1 norm (the sum of all 
absolute values in the vector), and c1 and c2 are parameters to penalize the sparsity in α and 
β. For simplicity, in this study, c1= c2 and 0 < c ≤ 1. 
The penalized multivariate analysis was performed with the “PMA” library in R (Witten et 
al., 2009). 
2.3.6 Performance evaluation 
We ran 5-fold cross-validation to evaluate the performance of the SVM and SCCA models. 
All models were assessed by counting the numbers of true positives (TP), true negatives 
(TN), false positives (FP), and false negatives (FN), and calculating overall predictive 
accuracy (accuracy = (TP+TN)/(TP+TN+FP+FN)), sensitivity (TP/(TP+FN)), and 
specificity (TN/(TN+FP)) (Baldi et al., 2000). Additionally, the receiver operating 
characteristic (ROC) curve, which is a graphical plot of the true positive rate (sensitivity), 
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against false positive rate (1-specificity) (Gribskov and Robinson, 1996) was used to 
evaluate the performance, and the area under the curve (AUC) was also calculated with 
ROCR package in R (Sing et al., 2005) where AUC = 1.0 represents a perfect classifier 
and AUC = 0.5 means a worthless test (Lobo et al., 2008). 
2.4 Results 
2.4.1 Datasets 
2.4.1.1 The fragment dataset 
We used a dataset of 30 086 compounds with between 4 and 20 non-hydrogen atoms out 
of a total of 93 902 with MeSH terms in PubChem (2013). After cleaning charges and 
eliminating duplicates, 148 310 out of 162 261 fragments from the clean fragment-like 
subset of ZINC were used as the set of substructures, of which 11 011 were observed in a 
total of 26 644 PubChem compounds using substructure search in Open babel 2.3.2 
(O'Boyle et al., 2011). 
It is clear that many toxic endpoints can be caused by very different compounds (Benigni, 
1991). However, it is still likely that highly similar structures can cause similar toxicities, 
and thus this situation could bias the results. Thus to further test the chemical diversity of 
the fragment data set, we computed the Tanimoto similarity index of the whole data set 
using MolPrint2D (Bender et al., 2004). From the distribution patterns of molecular 
similarity values among these 11 011 fragments (Figure 2.1), it is clear that most (~99%) 
of the values range from 0 to 0.4 (i.e. virtually no similarity in structure), suggesting that 
our data set is structurally diverse.  
2.4.1.2 The toxicity endpoint dataset 
The entire dataset contains 5 605 compounds linked to 1 477 toxicity endpoints, with a 
total 54 353 compound-toxicity associations and 115 639 fragment-toxicity associations.  
2.4.2 Toxic fragment analysis 
To understand the chemical fragments related to toxicities, frequency analysis was applied 
to recognize the structural alerts. Details of frequencies of each fragment occurred in 
different toxic classes with Obs/Exp > 1 and p < 0.05 were shown in Table S2.1 of  
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Figure 2.1 Histogram of the distribution of the molecular similarities between all fragment pairs 
Supplementary Materials. These 609 fragments reflected the chemical features of 234 
types of toxicity and can be considered as potential structural alerts to predict toxicity of 
uncharacterized compounds. Table 2.1 shows some well-known structural alerts that were 
detected in our study and their statistical performance.  
Table 2.1 Some examples of structural alerts 
Name Structure Endpoints Obs/exp 
 
P value 
 
Aniline 
 
hepatotoxicity 
nephrotoxicity 
1.40 
1.37 
0.0173 
2.67e-05 
Benzonitrile 
 
genotoxicity 3.96 0.0009 
Bromobenzene 
 
nephrotoxcity 2.20 0.0020 
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Several of the alerts identified correspond to compounds or moieties already associated 
with toxicities. For example, the aniline moiety, a common structural alert, is found in 
many drugs (Kalgutkar, 2015). Aniline groups can be oxidized to intermediates and 
transformed to phenylhydroxylamine and nitrosobenzene groups, which in turn can 
covalently bind macromolecules or radicals to induce toxicities (Kalgutkar, 2015). 
Benzonitrile is contained in some pesticides, such as ioxynil, chloroxynil, and bromoxynil, 
and it is reported that these compounds induce severe toxicity in human cells (Lovecka et 
al., 2015). 
Bromobenzene-induced nephrotoxicity is thought to occur after bromobenzene is first 
metabolized to 2-bromophenol and then to bromohydroquinone, which is then transported 
to the kidney where it induces toxicity (Schnellmann and Mandel, 1986). It is also thought 
to induce hepatotoxicity via GSH depletion, reduction of nucleophiles such as NAD(P)(H) 
Furan 
 
nephrotoxicity 
teratogenicity 
genotoxicity 
1.76 
1.78 
2.72 
0.0105 
0.0009 
1.23e-09 
Naphthalene 
 
nephrotoxicity 
teratogenicity 
genotoxicity 
3.12 
1.75 
3.26 
5.07e-05 
0.0039 
3.61e-20 
3-Ethyltoluene 
 
cardiotoxicity 
nephrotoxicity 
1.73 
1.34 
0.043 
0.014 
4-Aminophenol 
 
hepatotoxicity 
teratogenicity 
nephrotoxicity 
2.76 
1.57 
1.62 
0.0001 
0.0010 
0.0009 
4-Ethylphenol 
 
cardiotoxicity 2.52 0.0009 
Sulfanilamide 
 
epidermis necrosis 24.67 2.05e-08 
Thiazole 
 
neurotoxicity 1.96 0.0015 
Thiophene 
 
hepatotoxicity 
genotoxicity 
8.31 
2.10 
0.0004 
0.0008 
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and CoA, and by chemical intermediates binding to proteins (Schnellmann and Mandel, 
1986). 
Furan related compounds are involved in a wide range of toxicities (e.g., genotoxicity, 
nephrotoxicity and teratogenicity) and some mechanisms have been investigated (Moro et 
al., 2012). For example, furan could be activated by cytochrome P450 enzymes into 
reactive compounds such as α,β-unsaturated dialdehyde, cis-2-butene-1,4-dial, which can 
bind to nucleophiles to form cytotoxic adducts (Byrns et al., 2002). Another study showed 
that cis-2-butene-1,4-dial forms glutathione conjugates and protein adducts to amino and 
thiol groups of amino acids, leading to toxicity in the target organs (Chen et al., 1997).  
Naphthalene rings are implicated in various toxicities. The mechanism of naphthalene-
induced nephrotoxicity is first the metabolism by CYP450s into naphthalene epoxide, 
which induces serial reactions including GSH depletion, and naphthol or dihydrodiol 
production. The subsequent conversion to naphthalenediol and oxidation to 
naphthoquinone generates reactive oxygen species (ROS), leading to cell damage or death 
(Stepan et al., 2011). 
4-Aminophenol is known to be activated by liver enzymes into a quinoid structure (Fowler 
et al., 1991), which might contribute to the potential nephrotoxicity of compounds 
containing this. 
4-Ethylphenol induces toxicity by first binding macromolecules via the free electrons from 
oxidized substrates (e.g., phenoxy radicals, semiquinones and quinine methide) leading to 
additional ROS (Thompson et al., 1995). The acute toxicity of 4-ethylphenol has been 
assessed by a read-cross approach (Mellora et al., 2017), which correctly identified 
analogues of the 4-ethylphenol group as belonging to the same toxicity category. A 
literature review suggests the toxicity of substituted phenols is correlated with the 
formation of free radicals by abstracting a hydrogen radical from the phenolic hydroxyl 
group ultimately leading to cellular damage (Hansch and Gao, 1997). 
Because the thiophene moiety is more sensitive to S-oxidation, thiophene-containing 
drugs tend to be metabolized to reactive S-oxides in the liver where they can act as 
inhibitors of CYP450 enzymes (Liu and Uetrecht, 2000).  
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2.4.3 Prediction via support vector machines 
We then evaluated the capability of using the proposed structural alerts to predict 
uncharacterized compounds by machine learning methods. 3,743 compounds containing 
the 608 structural alerts (toxic fragments) and linking to the 234 toxic MeSH terms were 
found in our data set. Since the imbalance (the proportion of toxic and non-toxic cases) of 
the data set affects the learning process (Afzal et al., 2013), we reduced the classifiers to 
balance the positive (toxic) proportions increasing classifiers accuracy. This was achieved 
by removing the toxic terms that appeared in less than ten compounds. 
Having assessed which fragment or toxicity is present in any compound, we then defined a 
binary matrix for each compound where 1 indicates presence and 0 indicates absence of 
each fragment or toxicity. This led to a data set comprising 991 compounds containing 
415 proposed toxic fragments, and linked to 232 toxic terms, meaning a total of 647 
binary values for each compound (Supplementary Materials). 
Overall, we have then the potential to derive individual SVM classifiers for 232 different 
toxicity endpoints. We firstly applied 5-fold cross-validation support vector machines 
(SVM) to test the ability of predicting known toxicities by proposed structural alerts. The 
matrix was randomly divided into five roughly equal sized subsets, and then each subset 
was taken in turn as a test set, and the remaining four data sets as training sets to perform 
the prediction.  
We evaluated the performance by accuracy (correctly predicted endpoints / total endpoints 
predicted) and ROC curves (plots of true positive versus false positive rates). Due to the 
imbalance of the dataset, the sensitivity (true positive rate) and specificity (true negative 
rate) were also used to measure the overall prediction performance. Statistical results of 
these values were shown in Table S2.2 of Supplementary Materials. Parameters were 
chosen by using the AUC score as an objective function. The best result was gained by 
Gaussian RBF kernel when width parameter σ = 0.1 and regularization parameter C = 1.  
Cross-validation, provided it is done correctly, will show reliable accuracy for the 
predictors. However, ultimate tests come from data external to that within the system. To 
do this, we chose the best model trained by SVM and tested with the external validation 
set from ToxWiz which contained 200 compounds relating with known toxic endpoints, 
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e.g., hepatotoxicity, neurotoxicity, nephrotoxicity and genotoxicity to evaluate the 
predictive ability of external data. Since the external set was independent from the training 
and test set, the performance on the external set could reflect predictive capability. The 
results are shown in Table S2.2 and Table 2.2. The best results were at the highest 
accuracy of 0.894, 0.890, 0.874, 0.865 for predicting hepatotoxicity, neurotoxicity, 
nephrotoxicity and genotoxicity, respectively, which represented credible predictions. 
However, as Table S2.2 shows, most specificity values are much higher than sensitivity 
values, which means that the models have higher accuracy for predicting non-toxicities 
than toxicities. One reason might be that most toxic endpoints (e.g., splenotoxicity, scalp 
inflammation, cone degeneration) are rarely occurring during clinical trials. By contrast, 
the high-throughput screening methods identified many hepatotoxicity, nephrotoxicity, 
genotoxicity drug candidates at the preclinical stage. Therefore, the models are more 
capable to predict most common observed toxicities than rarely observed toxic terms.  
Table 2.2 Performances of some toxic endpoints based on SVM method 
Toxic endpoint Data set Accuracy Sensitivity Specificity 
 
AUC 
 
genotoxicity Training set 
Validation set 
0.865 
0.740 
0.904 
0.600 
0.828 
0.751 
0.934 
0.734 
hepatotoxicity Training set 
Validation set 
0.894 
0.685 
0.556 
0.467 
0.983 
0.935 
0.971 
0.756 
nephrotoxicity Training set 
Validation set 
0.874 
0.895 
0.747 
0.533 
0.954 
0.930 
0.948 
0.953 
neurotoxicity Training set 
Validation set 
0.890 
0.755 
0.896 
0.792 
0.883 
0.750 
0.953 
0.822 
We also performed predictions on 263 withdrawn drugs from the WITHDRAWN database 
(Siramshetty et al., 2016). 195 withdrawn drugs contained potential toxic fragments and a 
total of 117 drugs with seven types of toxicity were predicted based on these fragments by 
SVMs model (Table 2.3). Hepatotoxicity (103 cases) was the most commonly predicted 
toxic endpoint. Rare drugs were predicted to be neurotoxic, genotoxic, cardiotoxic, 
nephrotoxic, teratogenic and skin toxic. The remaining 78 drugs were not predicted to 
associate with any specific toxicity. This is likely because, firstly, the average accuracy of 
our models is limited to 0.87. Secondly, post-marketing drugs were recalled from the 
market due to various events, ranging from safety reasons to non-safety problems 
including inefficiency, manufacturing, regulatory concerns and business issues 
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(Siramshetty et al., 2016). Less than 10% of products were withdrawn worldwide and 
many withdrawals occurred unpredictably in one or two countries due to idiosyncratic 
drug reactions (Hussaini and Farrington, 2007). 
Table 2.3 Predicted toxic endpoints associated with withdrawn drugs 
Toxic endpoint Number of 
withdrawn 
drugs 
Main structural alerts 
cardiotoxicity 6 1-butanol; 1-pentanol; 1-pentene; 2,2-dimethylpentane; 2-
methylbutane; acetic acid; cyclohexane; tetraisopropoxytitanium; 
trans-2-pentene 
genotoxicity 7 aniline; ethylbenzene; chlorobenzene; pyridinium; 
chlorochromate; thiophene 
hepatotoxicity 103 4-aminophenol; acetic acid; aniline; anisole; bromobenzene; 
chlorobenzene; ethylbenzene; furan; P-cresol; phenetole; phenol; 
thiazole; thiophene; sulfanilamide 
nephrotoxicity 3 acetic acid; aniline; naphthalene; propionamide; thiophene 
neurotoxicity 10 1,6-hexanediol; 1-butanol; 1-pentanol; ether; ethylbenzene; 
tetraisopropoxytitanium 
skin toxicity 1 aniline; ethylbenzene 
teratogenicity 2 ether 
Figure 2.2 shows some details for a selection of predictions. Many of these drugs are 
metabolized by CYP450s to form reactive metabolites, available of GSH depletion and 
binding to cellular proteins leading to toxicities and ultimate withdrawal from the market. 
For instance, NADPH-dependent covalent binding in human hepatocytes has been found 
in the metabolites of the uricosouric drug benzbromarone (McDonald and Rettie, 2007). 
Elsewhere, monohydroxylation catalyzed by CYP3A4 on the aniline moiety in the 
analgesic and antipyretic drug acetanilide apparently causes the formation of some 
intermediates that can be further metabolized to reactive quinone-imine species (Stepan et 
al., 2011). Ticrynafen can form reactive intermediate via epoxidation or S-oxidation of its 
thiophene fragment catalyzed by CYP450s. 
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Figure 2.2 Examples of chemical fragments (highlighted in red) that predicted to lead to toxicities in drugs 
withdrawn from the market. 
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2.4.4 Prediction via sparse canonical correlation analysis 
To explore how chemical fragments might be linked to toxicity endpoints, we employed a 
methodology similar to one used previously (Pauwels et al., 2011; Seoane et al., 2014), 
namely sparse canonical correlation analysis (SCCA). This technique can obtain the 
maximized correlation between the linear combinations of variables from two high-
dimensional heterogeneous datasets, e.g., a linear combination of chemical fragments and 
a linear combination of toxicity endpoints. SCCA can display a global view of the dataset 
by reducing variables into only a small number of dimensions that capture the main 
properties, for instance, chemicals containing the same substructures could have the 
similar toxicity endpoints. In our simulated study, two datasets containing categorical 
variables (e.g., 0, 1) - X (compound-fragment matrix) and categorical variables (e.g., 0, 1) 
- Y (compound-toxicity matrix), consisting of p (415 fragments) and q (232 toxicity 
endpoints), respectively, and n = 991 samples were used. First, we normalized variables of 
X and Y by subtracting the column means and dividing by the column standard deviations 
to delete null columns where all values were the same. For simplicity, the simulation was 
standardized by replacing variance-covariance matrices with identity matrices in equal 2.3. 
Then K is computed as the covariance between standardized datasets X t and Y t: 
K = Cov(X t , Y t ) = Σxt Y t                                                                                                (2.5) 
The results of this process are weight vectors, u1 and v1, in the linear combinations of 
variables from datasets X and Y. 
2.4.4.1 Performance evaluation 
We accessed the performance of SCCA using 5-fold cross-validation, thus datasets X and 
Y were split into five groups and each group takes turns to be the test set. Figure 2.3 
shows the ROC curve for the SCCA method where predictions for all toxicity endpoints 
are combined. With the parameters c1 = c2 = 0.04 and m = 100 for SCCA, the model 
obtained the best AUC score (0.801). The accuracy of individual toxicity endpoints 
(boxplot in Figure 2.4), obtained with the parameters c1 = c2 = 0.04 and m = 100.  
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Figure 2.3 ROC curves in the 5-fold cross-validation to evaluate the performance of SCCA 
 
Figure 2.4 Boxplot of the AUC scores for individual toxicity endpoints to evaluate the performance of 
SCCA 
The weight vectors for chemical fragments and toxicity endpoints were investigated and 
the index-plots of the first three canonical components were shown in Figure 2.5. Most all 
elements in the weight vectors in SCCA are zero in each component, which means SCCA 
can extract a small number of more selective and informative correlations between 
fragments and toxicities without losing performance. 
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Figure 2.5 Index-plot of weight vectors for chemical fragments (left) and toxicity endpoints (right) extracted 
by SCCA 
2.4.4.2 Extracted sets of chemical fragments and toxicity endpoints 
The above results prompted us to examine selected correlations of chemical fragments 
with toxicity endpoints in each canonical component extracted by SCCA for biological 
interpretations. Each component shows only a small set of chemical fragments related to a 
small set of toxicity endpoints. In each component of SCCA, there are two sets of 
compounds with high scores selected: one is the compounds with highest scores 
containing the associated chemical fragments, and the other is the compounds with highest 
scores containing the associated toxicity endpoints. A correlation coefficient is calculated 
to estimate the importance of the component correlation. Table 2.4 reports some 
components with higher coefficients clustering specific chemical fragments and toxicity 
endpoints in a small number of compounds. The results for the complete list can be found 
in Table S2.3. Most putative mechanisms of toxicity for the fragments are unknown, 
however, some plausible mechanistic explanations could be predicted by interrogation of 
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the literature. 
Table 2.4 Chemical fragments with significant correlations to toxic endpoints 
Canonical 
component 
Correlation 
coefficient 
Fragments with high 
scores 
Toxicity 
endpoints 
with high 
scores 
High scoring 
compounds 
(fragments) 
High scoring 
compounds 
(toxicity 
endpoint) 
59 0.988 
 
pyrimidine derivatives 
glioblastoma 
necrosis 
theophylline; 
tegafur; idoxuridine; 
floxuridine 
theophylline 
55 0.980 
 
phenol derivatives 
thyroid 
fibrosis 
 
equol;  
6,8-dimethoxy-3-
methyl-3,4-
dihydroisocoumarin;  
3-(2,3,4-
trimethoxyphenyl)ac
rylic acid 
equol 
48 0.816 
 
thiazole derivatives 
heart muscle 
necrosis 
thiamine; 
pramipexole 
pramipexole 
18 0.777 
 
indole derivatives 
liver 
ischaemia 
melatonin; 
hydroxyindoleacetic 
acid; 5-
hydroxytryptophan; 
norharman; harmine; 
clausine E 
clausine E; 
serotonin; 
melatonin; 
hydroxyindoleace
tic acid; 5-
hydroxytryptopha
n 
65 0.767 
 
t-cell necrosis urinastatin; 
furapyrimidone; 5-
nitro-2-
furylpropionamide; 
4-
hydroxynitrofurazon
furapyrimidone; 
4-
hydroxynitrofura
zone 
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e; methoxsalen; 
furanodienone; 
2,3,4,7,8-
pentachlorodibenzof
uran 
75 0.706 
 
halogenated derivatives 
testis 
degeneration 
pentabrominated 
diphenyl ether; DDT 
pentabrominated 
diphenyl ether; 
firemaster BP-6; 
dichlorodiphenyl 
dichloroethylene; 
DDT 
36 0.701 
 
thiophene derivatives 
coagulation ticlopidine; 
methapyrilene 
ticlopidine; 
fenfluramine; 
aspirin 
Compared with frequency analysis, SCCA extracted associations of a set of fragments 
with similar structures and a set of toxicity endpoints. The substructures responsible for 
toxicities can be obtained according to chemical categories: indole derivatives, thiophene 
derivatives, thiazole derivatives, phenol derivatives, etc. This makes the explanations of 
mechanisms more straightforward. For example, component 75 contains the halobenzene 
and halogenated hydrocarbon substructures linked to testis degeneration. The toxic effects 
are likely from cytochrome P450-dependent reduction to the reactive forms (halobenzene 
epoxide and trichloromethyl radical) which can bind to proteins to induce the toxicity 
(Allen et al., 1979; McGregor and Lang, 2000). 
2.4.4.2 Toxicity prediction for withdrawn drugs 
The prediction results for withdrawn drugs are shown in Table S2.4. Compared with SVM, 
SCCA tends to predict the specific toxicities (e.g., pulmonary oedema, neutrophil 
phagocytosis) that are associated with special drug clusters, while the common toxic terms 
(e.g., hepatotoxicity, nephrotoxicity) are rarely predicted with high scores for a drug. For 
example, amphetamine, dexfenfluramine, tranylcypromine, terfenadine were predicted 
with higher scores for a specific toxic term “valvulopathy” - a main cause of congestive 
heart failure (Carabello and Crawford, 1997), of which amphetamine and dexfenfluramine 
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were reported to associate with cardiac valvulopathy (Rothman et al., 2000).  
2.4.5 Mechanism study of toxicity 
Ideally, statistically significant predictions should be complemented with putative 
mechanistic explanations for why they are predicted. An emerging theme from the 
literature about several fragments suggests the finding that covalent binding by structural 
alert moieties to cellular proteins could be a direct cause of toxicities. Several of these 
moieties have been seen within protein three-dimensional structures. We identified these 
by searching for their occurrence in ligands within known structures (Figure 2.6). 
 
Figure 2.6 Interactions of selected structural alerts with biomolecules (black dashed lines show hydrogen 
bonds and green lines indicate hydrophobic interactions). The interactions provided by PoseView are 
extracted from the protein databank (PDB; rcsb.org). 
It is also important to note that toxicity owing to a structural alert is conditional. The toxic 
structural alert-containing drugs could be hazardous or safe depending on their metabolic 
pathways and the bioactivity of the structural alert (Rybacka et al., 2015). Most toxic cases 
are caused by the reactive metabolites of the drugs instead of the drugs themselves. 
Chapter II 
 
35 
XenoSite can predict when structural alerts of furan, phenol, nitroaromatic, and thiophene 
will be bioactivated in drugs (Dang et al., 2017). We used the model of SMARTCyp in 
XenoSite to predict the six thiophene-containing drugs: methapyrilene, suprofen, 
ticrynafen, zileuton, dorzolamide, and olanzapine (Rydberg et al., 2010) (Figure 2.7). The 
first four drugs are shown to form reactive metabolites through the S-oxidation or 
epoxidation of thiophene (colored in red) by CYPs and they have been withdrawn from 
the market, while the thiophene groups contained by the last two drugs dorzolamide and 
olanzapine do not undergo bioactivation nor toxic (colored in green and blue). 
 
Figure 2.7 Metabolism model predicts whether thiophenes are bioactivated by CYPs. SMARTCyp model is 
used to shade atoms of drugs, ranging from white (0.0) to green (0.5) to red (1.0). The red represents the 
bioactivated parts and the blue parts are not bioactivated. 
Besides direct drug targets such as nuclear receptors, drug transporters, drug metabolizing 
enzymes with known toxicity associations, other protein interactions (i.e. off-target 
interactions) might also contribute to toxicities. We constructed a network (Figure 2.8) by 
integrating the interactions of the structural alert benzbromarone with gene expression 
data from TG-GATEs and associated pathways defined by gene ontology (GO) categories 
(Ashburner et al., 2000). A more systematic study relating gene expression to toxic 
response is given in Chapter III. Benzbromarone was withdrawn from the market in 
France due to its hepatotoxicity. It is metabolized by CYP3A4 to 1'-
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hydroxybenzbromarone and by CYP2C9 to 6-hydroxybenzbromarone, which is be further 
metabolized by CYP2C9 and CYP1A2 to 5,6-dihydroxybenzbromarone. The structural 
alert Acyclic di-aryl ketone moiety can be oxidized to 2,6-dibromohydroquinone and 2,6-
dibromobenzoquinone which might induce hepatotoxicity by covalent binding with 
proteins (Kitagawara et al., 2015). 
 
Figure 2.8 Network of benzbromarone-induced hepatotoxicity response. Genes are shown in circles; those 
in red are up-regulated and blue are down-regulated in rat liver (in vivo). Structural alerts are highlighted 
with stars. 
Single nucleotide polymorphisms in CYP2C9 might be associated with the individual 
toxicity response to benzbromarone (Takahashi and Echizen, 2003). 36 variations of 
CYP2C9 from 1000 Genomes Phase 3 (The 1000 Genomes Project Consortium, 2015) 
were tested using Mechismo (Betts et al., 2015). Four of these, R124L, S127F, M240T 
and I359L at the binding sites are predicted to affect the bindings of triflucan, bifonazole, 
flurbiprofen and piperazine, which might increase and/or inhibit the effectiveness of those 
drugs (Figure 2.9). A systematic analysis of associations between polymorphisms and 
toxicity is discussed in Chapter V. 
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Figure 2.9 Structures of CYP2C9 mutations in contact with four drugs 
2.5 Conclusion and discussion 
The systematic analysis of a large number of chemical compounds and their links to 
toxicity terms revealed that statistics (e.g., frequency analysis) and machine learning 
methods such as both SVM and SCCA are capable of identifying structural alerts 
associated with toxicity. We found hundreds of structural alerts, including some known 
alerts like aniline, furan, or phenol. Many of the identified fragments are known to form 
reactive metabolites that might induce toxic effects. This finding has been used previously 
to aid quantitative structure-toxicity relationships (QSTR) analyses (e.g., quetiapine versus 
clozapine (Nelson, 2001)), suggesting that the presence of the fragments leads to a higher 
incidence of toxicity and that they should be avoided in drug development where possible.  
Nevertheless, some structural alerts can be beneficial for activity. For example, quetiapine 
and clozapine’s structurally similar agent, olanzapine, contains the aniline structural alert 
and is indeed known to form reactive metabolites, and associated covalent bonds with 
proteins, but is nevertheless devoid of toxic effects (Nelson, 2001). Predictions from such 
alerts thus need to be considered with caution.  
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The results in this chapter also hint that toxicity predictions should be coupled to detailed 
mechanistic analyses. A comprehensive understanding of how bioactivation pathways 
produce toxic effects can come by integrating gene expression data from in vivo and in 
vitro models. Other studies suggest this strategy could be fruitful. For example, the 
withdrawn antibiotic trovafloxacin shows significantly different gene expression patterns 
(related to genes involved in oxidative stress response) compared to structurally similar 
fluoroquinolones still on the market (Stepan et al., 2011). A recent study also suggests that 
shifts in IL-6/TNF-α ratios play a role in immune-mediated trovafloxacin-induced 
hepatotoxicity (Bonzo et al., 2015).  
Several genetic studies indicate that polymorphisms in drug metabolizing enzymes could 
lead to individual differences in reactive metabolite formation and thus different responses 
to xenobiotics (Williams and Park, 2003). For instance, it has been suggested that 
polymorphisms in the enzyme N-acetyltransferase 2 (NAT2) are responsible for the 
severity of hepatotoxicity of isoniazid, an antibiotic used for the treatment of tuberculosis. 
The mutants of NAT2 were found to increase the risk of hepatotoxicity by activating the 
hydrazine group (a structural alert) to form N-acetylisoniazid intermediate (Huang, 2007). 
Overall, application of structural alerts to filter drug candidates should be complemented 
by putative mechanistic insights based on existing biological data. This is a subject that we 
discuss in the following chapters. 
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CHAPTER III: Deciphering mechanisms of drug action and 
toxicity by integrating gene expression signatures, biological 
features and chemical features 
3.1 Abstract 
The molecular mechanism for how xenobiotics exert beneficial or detrimental effects on 
biological systems is important for many applications in pharmacology and biomedicine. 
Gene expression screens performed systematically on many compounds in multiple 
tissue/species systems provide opportunities to investigate principles of the molecular 
impact of xenobiotics on biological systems. We analyzed the TG-GATES gene 
expression and pathology data on 131 compounds in liver or kidney tissues and cell lines. 
We found that in vivo and in vitro data are only rarely similar and gene expression profiles 
of in vivo rat liver data are more informative about mechanism than other datasets. 
Clustering compounds according to expression signatures forms groups with similar 
therapeutic characteristics and/or mechanism of drug actions, with relatively few clusters 
arising owing to a similarity in toxic response, suggesting that drug mechanism-of-action 
is the predominant effect observed in expression studies. We also found correlations 
between overexpression of genes related to cell proliferation and drug metabolism with 
compound solubility, and between structure alerts (e.g. acetanilide, 4-chlorotoluene) and 
the expression of genes associated with the mechanisms of drug-action, although we found 
no correlation between any measure of gene expression and molecular structure similarity. 
Our findings suggest that simultaneous exploration of biological, chemical features and 
gene expression changes can enrich understanding of drug action and ultimately help drive 
alternatives to animal models. 
3.2 Introduction 
The advent of high-throughput techniques to study gene expression led, when used in 
toxicology studies, to the field of toxicogenomics, where changes in gene expression are 
used to identify potential markers of compound toxicity (Afshari et al., 2011). There have 
been a number of success stories, for example, where particular biomarkers or gene 
signatures have been identified using these techniques (Caiment et al., 2014; Ichimura et 
al., 1998; Yamada et al., 2012). Moreover, despite many studies both in toxicogenomics, 
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but also more generally in chemically induced gene expression changes, the relationship 
between a chemical features and biological response remains elusive. Gene expression 
profiling has been a popular technique to study responses to cell or tissue stimuli and has 
been used, for example, to detect differences between normal and diseased tissues 
(Velculescu et al., 1999), to detect RNA expression responses in tissues that have been 
treated with drugs (Gray et al., 1998) and to detect the mechanisms underlying biological 
pathways (Bertilsson et al., 1998). Previous studies have shown that chemical features can 
be related to gene expression. For example, there are correlations between chemical 
structure of cancer drugs and gene expression (Blower et al., 2002). Elsewhere distinct 
chemical properties correlate with specific cellular responses: for instance, hydrophobic 
properties correlate strongly with DNA damage response, and hydrogen bonding is linked 
to metabolic stress (Khan et al., 2012). A reliable connection between one class of up-
regulated genes induced by certain compounds in the liver and their chemical information 
found in ECFP4 fingerprints has also been predicted (Fernald and Altman, 2013).  
More recently, a variety of public and commercial databases of expression profiles have 
been developed and presented many advantages to the identification of pharmacological or 
toxic phenotype of new chemical entities. For example, the Connectivity Map dataset 
contains (in build 02) more than 7 000 microarray expression profiles from cultured 
human cells treated with 1 309 bioactive small molecules and has been used in drug 
repositioning and for elucidating the mechanism of action of drugs (Lamb et al., 2006). 
The Open Japanese Toxicogenomics Project-Genomics Assisted Toxicity Evaluation 
System (Open TG-GATEs) consists of gene expression data and pathological data from 
131 different compounds, mainly medical drugs, given in vivo and in vitro to rats and 
human at different doses and time points and then measured in liver and kidney tissues 
and cell-lines (Uehara et al., 2010). These data have been employed in studies to identify 
candidate biomarker genes and to construct prediction models for hepatotoxicity (Gao et 
al., 2010; Hirode et al., 2009; Kiyosawa et al., 2007; Omura et al., 2007; Uehara et al., 
2011, 2008a), nephrotoxicity (Kondo et al., 2009) and hepatocarcinogenicity (Uehara et al., 
2011, 2008b). Such studies have provided data and approaches to systematically compare 
the gene expression profiles in vivo and in vitro, across different species and within 
different tissues, and to explore the relationships between biological features, chemical 
features, gene expression profiling and pathology. In this chapter, we explore how 
toxicogenomics signatures (within the TG-GATEs project) relate to chemical features and 
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how well expression changes capture toxic or other mechanistic information related to 
drug response. 
3.3 Methods 
3.3.1 Toxicogenomics datasets 
The TG-GATEs (http://toxico.nibiohn.go.jp/english/) database (Phase I) contains 131 
compounds, mainly drugs (Uehara et al., 2010). For the in vivo studies, selected rats were 
treated with both a single-dose, consisting of four time points (3h, 6h, 9h and 24h) with 
three doses (low, middle and high), and a repeated-dose, consisting of four treatment 
durations (4d, 8d, 15d and 29d) with three dose levels (low, middle and high). Gene 
expression of livers and kidneys from the rats were profiled with three animals in each 
group. In the in vitro studies, the primary rat hepatocytes and primary human hepatocytes 
were treated at three time points (2h, 8h and 24h) with three concentrations (low, middle 
and high) by each of the 131 compounds. All the studies had time-match controls.  
3.3.2 Microarray data and pathological data processing 
Affymetrix CEL-files were downloaded from the Open TG-GATEs database 
(http://toxico.nibiohn.go.jp/datalist.html) and processed by the Bioconductor package 
simpleaffy (Wilson and Miller, 2005) for generation of expression values for each probe 
set using the robust multiarray averaging (RMA) method (Irizarry et al., 2003). Probe sets 
were then reannotated to genes using custom CDF file (version 15.1.0) (Dai et al., 2005). 
Finally, the replicate samples were summarized by taking the average and differential 
expression was calculated as log 2-ratio compared to the time-matched controls. Statistical 
significance p-values were assigned using a modified t-test (Storey and Tibshirani, 2003). 
For subsequent analysis we considered genes which had a significant (at least 2 fold) 
increase or decrease (p < 0.01) in expression by any of the 131 compounds at any dose or 
time point (Table S3.1). 
Histopathological records for the rat in vivo data were obtained from the TG-GATEs web 
site. Pathological observations were coded from 0 to 4 based on intensity by pathologists: 
0=no change, 1=minimal, 2=slight, 3=moderate, 4=severe and values from replicate 
samples belonging to each instance were averaged. We then summed up the values of all 
histopathology findings in each organ and used them as an overall measurement of 
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pathology classes (Table S3.3). 
3.3.3 Principal component analysis (PCA) and hierarchical clustering analysis (HCA) 
Principal component analysis (PCA) was performed to visualize the gene expression data 
in two dimensions, i.e., the first two principal components with highest variance. 
Specifically, a matrix (100 top-ranking genes vs compounds) was built with each element 
representing the expression of the 100 genes with highest fold change (absolute values) in 
in vitro rat hepatocyte (Table S3.2). Then, a PCA using the prcomp command in R (R 
Development Core Team, 2012)) was implemented on this matrix to investigate the batch 
effects in the TG-GATEs. 
Furthermore, for investigating the gene expression similarity between any two compounds, 
we calculated a Jaccard index (intersection divided by union) as a measure of similarity, 
counting each gene/expression-direction pair once. We then used the hierarchical cluster 
analysis program, OC (GJ Barton, University of Dundee) to obtain compound clusters 
based on these scores. We employed “complete” linkage options to divide the whole set 
into discrete clusters. Tree figures were generated using iTOL (Letunic and Bork, 2011). 
3.3.4 Biological data collection and visualization 
We extracted ATC-classes (i.e. descriptions of therapeutic use) for all 131 chemical 
compounds from the WHOCC database (http://www.whocc.no/). Annotations of toxic 
endpoints induced by chemicals were extracted from the publications of toxicogenomics 
experiments (http://www.toxwiz.com/) and drug-target interactions were assigned using 
DrugBank (Knox et al., 2011). 
We constructed networks of genes and their interactions from the rat metabolic and 
signaling pathways in KEGG (Kanehisa et al., 2012), and rat protein-protein interactions 
from STRING (Franceschini et al., 2013) and rat chemical-protein interactions from 
STITCH (Kuhn et al., 2014). We considered both experimental and predicted with high 
confidence (score > 0.7) interactions in STRING and STITCH.  
3.3.5 Chemical data collection and visualization 
We extracted structure files for 98 compounds from PubChem (Bolton et al., 2008). After 
adding hydrogen atoms, transforming to 3D structures, chemical properties (e.g. number 
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of hydrogen bond acceptors and donors, LogP, topological polar surface area) were 
computed by Open Babel (v. 2.3.1) (O’Boyle et al., 2011). The structure similarity 
between any two compounds was calculated based on Molprint 2D using Tanimoto 
coefficient (Bender et al., 2004), as shown in Chapter II Methods.  
We downloaded 162 261 clean fragment structures filtered according to the rule-of-three 
selection criteria from ZINC database (version 12, Irwin and Shoichet, 2005) and cleaned 
charges manually. For substructure searching, we used structural fingerprints from Open 
Babel (v. 2.3.1) and PubChem (Bolton et al., 2008).  
We matched 1 332 distinct small fragments from ZINC database to 98 compounds that 
modulated gene expression in vivo rat liver. We then created a binary feature matrix with 
98 rows (one for each compound), and 1 332 columns (one for each small fragment). 
Entries in the binary feature matrix were set to 1 if the fragment was found in the 
compound, otherwise the entries were 0. We then performed principal component analysis 
on this 98 x 1 332 matrix.  
3.3.6 Sparse canonical correlation analysis (SCCA) 
See sparse canonical correlation analysis (SCCA) in Chapter II Methods. 
3.4 Results 
3.4.1 Gene expression quality controls 
Since the large scale of transcriptomics data were from several contributors, differences 
arising from subsets of sample batches are unavoidable. In order to identify the reliability 
of the genes and eliminate implausible data, here, we executed curation steps including 
controlling batch effects, assessing reproducibility across replicates and analyzing 
concentration-response relationship presented by Grinberg et al. (Grinberg et al., 2014).  
3.4.1.1 Batch effects 
PCA was performed for the expression values of 229 probe sets representing the 100 
genes with the highest fold change (absolute values) across 130 compounds (carbon 
tetrachloride was excluded due to unavailable data) in the 24h-high concentration of rat in 
vitro subset (Table S3.2). PCA applied to two replicates and two controls for each probe 
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which illustrates their locations within four clusters (Figure 3.1 (a)). Using the mean 
values of the replicates and the mean values of controls gives similar clusters (Figure 3.1 
(b)). When controls and the corresponding treated samples are connected by lines, we see 
two main clusters revealing that the difference between the clusters is a consequence of 
batch effects in microarray data (Figure 3.1 (c)) and that, after subtracting the controls 
from the corresponding treated samples, the initial clusters are not observed any more 
(Figure 3.1 (d)), suggesting that batch effects were eliminated by this step. 
Figure 3.1 Principle component analysis for rat in vitro gene expression data obtained after treatments of 
131 compounds with high dose level at 24h time point. The red and blue symbols represent the controls and 
treated samples, separately (a) PCA for all controls and samples (b) PCA for using the mean values of 
controls and replicates (c) Connecting lines between controls and the corresponding treated samples (d) PCA 
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after subtracting the controls from the corresponding treated samples 
3.4.1.2 Reproducibility 
We checked the distance between replicates and compared this to the influence caused by 
the test compound. Figure 3.2 shows the frequency distributions for Euclidean distances 
between replicates and control-treatment pairs tested at the 24h time point at high 
concentrations, where 90% of distances between replicates are lower than 14, while 92.5% 
distance between control-treatment pairs are larger than 14. The median distance between 
replicates is 5.3-fold lower than that between control-treatment pairs, which suggests that 
the reproducibility between replicates is acceptable. 
 
Figure 3.2 Frequency distribution of Euclidean distance between all replicate sample pairs (blue) and 
control-treatment sample pairs (red) for 24h high dose treatment  
3.4.1.3 Number of dysregulated genes per compound 
The number of dysregulated genes among the 100 top-ranking genes (Table S3.4) in rat in 
vitro subset was checked separately for all nine combinations of dose level (low, middle, 
and high) and time-point (2h, 8h, and 24h) (Figure 3.3). It shows that the number of 
dysregulated genes is different between the compounds and the top 100 genes were 
dysregulated by 112 of 131 compounds. Some of the well-known toxic compounds such 
as carbon tetrachloride weakly dysregulated a few genes in TG-GATEs. In the 
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comparisons of the high versus middle concentration for the exposure periods of 2h, 8h, 
and 24h, giving number of compounds ratios of fewer regulated to more regulated genes 
of 1/20, 1/77, and 1/95, respectively, showing overall greater changes in response to a 
higher dose. These ratios are 3/3, 3/23, and 2/42 when comparing the middle to low 
concentration, also showing generally a stronger effect for a higher dose. The data in 
which the genes dysregulated at a low concentration remain unaltered at a higher 
concentration should be treated with caution. 
3.4.1.4 Concentration-response relationship 
We then investigated the concentration-response relationship for individual genes (Table 
S3.5). All upregulated genes with at least 2-fold change at any dose level (low, middle, or 
high) after 24h treatment with 131 compounds were determined (Figure 3.4). Of the 42 
compounds which induced significant upregulation of a minimum of ten genes, 16 show 
that genes become upregulated from the low to the middle and from the middle to the high 
concentrations (e.g., tannic acid, clofibrate, naproxen and colchicine). For 22 compounds 
we see differences between high and middle, but not middle and low (e.g., cephalothin, 
paraverine, ibuprofen and sulpiride). Two compounds (phenobarbital and acetaminophen) 
upregulated most genes from the low to the middle but downregulated from the middle to 
the high concentration. For two others (puromycin aminonucleotide and WY-14643), 
genes are upregulated at low, but not at middle or high doses. There is no obvious 
explanation for these exceptions, though it is possible that higher doses lead to drastic 
alterations in physiology (possibly leading to death of the animal) that are not captured in 
the expression set. Nevertheless, the majority of compounds show an expected drug-
concentration-response relationship. 
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Figure 3.3 Number of dysregulated genes per compounds. The X axes lists 112 compounds that were tested 
at the indicated time point and concentration and the Y axes illustrates the number of genes affected among 
the 100 strongest dysregulated genes.  
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Figure 3.4 Expression levels of the most affected genes upregulated at three concentrations after 24h 
exposure 
3.4.2 Gene expression profiles reflect common pharmacology  
We clustered compounds according to an overall measure of gene expression similarity 
(considering all genes dysregulated at any dose or time point equally) and inspected the 
resulting groups for similarities in action of drug, toxicity, or drug target.  
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3.4.2.1 In vivo gene expression clusters 
The dendrogram of in vivo gene expression data includes 98 out of 131 compounds that 
had signatures with at least ten and at most 200 significantly changed genes (Figure 3.5). 
Compounds are in three main clusters with multiple sub-clusters. Several sub-clusters 
(enclosed by boxes in Figure 3.5) show similar ATC classifications or drug targets and 
suggesting that drug action is a major determinate of gene expression. Only two sub-
groups show a clear clustering according to toxicity (hepatotoxicity). 
 
Figure 3.5 Dendrogram showing the clustering of 98 compounds based on gene regulation in vivo rat liver. 
The enriched biological features are labeled on the tree. The exact black color displays highest value of 
pathology classes and the colors gradually fading towards white representing the lower values. 
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Figure 3.6 Networks of genes changed by chemicals. Nodes are distinguished by different shapes and colors 
including compounds represented by 2D structures (round rectangles), drug targets (green ellipses), drug 
metabolizing genes (triangles), genes (ellipses), up-regulated genes (red ellipses), down-regulated genes 
(blue ellipses), and drug targets (green ellipses) and edges includes drug-target association, target-pathway 
association and gene-gene association. (a) network of genes changed by cardiovascular drugs (e.g. 
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benzbromarone, clofibrate, fenofibrate, gemfibrozil, ibuprofen and simvastatin) (b) network of genes 
changed by musculoskeletal drugs (e.g. naproxen, meloxicam, penicillamine, lornoxicam, mefenamic acid 
and sulindac) (c) network of genes changed by one group of CNS drugs (e.g. trimethadione, diazepam, 
carbamazepine and hydroxyzine) (d) network of genes changed by another group of CNS drugs (e.g. 
amitriptyline, imipramine, phenobarbital, haloperidol and iproniazid) (e) network of genes changed by one 
group of hepatotoxicants (e.g. acetamidofluerene, monocrotaline, carbo tetrachloride, naphthyl 
isothiocyanate, acetaminophen and bromobenzene) (f) network of genes changed by another group of 
hepatotoxicants (e.g. hexachlorobenzene, cisplatin, methapyrilene, nitrosodiethylamine, disulfiram, 
flutamide, phenytoin and omeprazole) 
There is one large sub-group of predominantly cardiovascular agents (ATC code: C): 
ibuprofen, fenofibrate, clofibrate, benziodarone, simvastatin and gemfibrozil. These drugs 
target either PPARA or PPARG, and nine of the common dysregulated genes are likely 
altered by PPAR transcriptional activation/suppression events. Twelve of 29 of the genes 
changed by at least four agents in this cluster are involved in peroxisome proliferation 
events (Cd36, Ehhadh, Pex11a, Me1, Acaa1, Angptl4, Crat, Cyp4a1, Ech1, Aqp7, Cpt1b 
and Lpl), together with fatty acid metabolism, including genes for fatty acid 
elongation/degradation and lipid metabolism (e.g., Acot1, Acot2, Acot3, Acot4, Dci, Eci1 
and Apoa4) (Table S3.6, Figure 3.6(a)). 
The sub-cluster of musculoskeletal drugs (ATC code: M) comprises six anti-inflammatory 
drugs (naproxen, meloxicam, penicillamine, lornoxicam, mefenamic acid and sulindac), 
with similar expression patterns. 14 genes were changed by at least five of those 
compounds (Table S3.7). The mechanism of anti-inflammatory drugs is mainly driven by 
Ptgs1 and Ptgs2, and genes centering around the pathway of anti-inflammatory were up- 
or down-regulated by all the six compounds, such as Cxcl1, Cd36, Mt1a, Mt2A, Lbp and 
Spink3 (Figure 3.6(b)). Another sub-cluster contains three additional anti-inflammatory 
drugs, phenylbutazone, bendazac and chlormezanone, with eight common up-regulated 
genes affecting retinol metabolism, glutathione depletion and drug metabolism (Abcc3, 
Aldh1a1, Aldh1a7, Cyp2b1, Cyp2b2, Gadd45b, Gsta5, and Rgd1562844; Table S3.7).  
A group of central nervous system (CNS) drugs (ATC code: N) lie in two subclasses. The 
first group includes trimethadione, diazepam, hydroxyzine and carbamazepine that all 
have been demonstrated to enhance the expression of drug-metabolizing genes, such as 
aldehyde dehydrogenase (Aldh1a1 and Aldh1a7), cytochrome P450 (Cyp2b1 and Cyp2b2), 
UDP glucuronosyltransferase (Ugt2b and Ugt2b1), glutathione S-transferase alpha 5 
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(Gsta5) and carboxylesterase 2 (Ces2c and Ces2l) (Table S3.8, Figure 3.6(c)). Two of 
those compounds, trimethadione and carbamazepine, commonly affected all 15 genes in 
the network, while others affected nine. Compounds in the other CNS drugs cluster 
containing imipramine, amitriptyline, phenobarbital, iproniazid and haloperidol ) often (at 
least three) dysregulated Cdc2, Cdkn3, Rrm2, Ccna2, Ccnb1, Ccnb2, Ckap2, Ns5atp9 and 
Ect2, which are related to the cell cycle, and up-regulated genes for neuroactive ligand-
receptors, such as Prlr, in addition to drug-metabolizing enzymes (Table S3.8, Figure 
3.6(d)). One of the similarities between the two networks (Figure 3.6(c) and Figure 
3.6(d)) is that genes dysregulated by all CNS drugs interact with protein kinase A (PKA), 
suggesting that their therapeutic mode of action is at least, in part, linked to the 
cAMP/PKA signaling pathway.  
There are also some compound clusters where common differentially expressed genes 
correlated roughly with a similarity in toxicity. For instance, bromobenzene, 
acetaminophen, carbon tetrachloride, monocrotaline, acetamidofluorene and naphthyl 
isothioxyanale are all hepatotoxic and at least four of them affected genes strongly 
associated with liver toxicities (Table S3.9). These include several genes encoding drug 
metabolizing enzymes and transporters (Aldh1a1, Akr7a3, Asns, Gpx2, Aldh1a7, Gsta5, 
Abcb1a, Abcb1b and Abcc3; Figure 3.6(e)). These principally work as protective enzymes 
responding to oxidant stress in phase II or III drug metabolism (Tanaka et al., 2007). 
Similarly, in the cluster including disulfiram, flutamide, methapyrilene, 
nitrosodiethylamine, cisplatin, hexachlorobenzene, omeprazole and phenytoin, both affect 
the genes for the first group in addition to down-regulating genes related to lipoprotein 
secretion (Apoa4, Scd and Scd1) (Figure 3.6(f)). The inhibition of lipoprotein secretion is 
known to play a role in hepatocellular necrosis and steatosis (Gao et al., 2010). Aside from 
these examples, the grouping of compounds according to gene-expression similarity 
shows little overall overlap with observed pathology outcomes (black boxes in Figure 3.5). 
3.4.2.2 In vitro gene expression clusters 
The dendrogram (64 compounds) for in vitro rat liver (Figure 3.7) also shows clusters 
more evidently related to drug action than toxicity. Some clusters resemble the in vivo 
conditions, such as that for cardiovascular drugs (simvastatin, benziodarone and 
clofibrate), CNS drugs (imipramine, iproniazid and amitriptyline), and alkylating agents 
(cisplatin and carboplatin). 
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Figure 3.7 Dendrogram showing the clustering of 64 compounds based on gene regulation in vitro rat 
hepatocytes. The enriched biological features are labeled on the tree. 
In In vitro array system only three genes related to the PPAR signaling pathway (Acot1, 
Ehhadh, and Angptl4) were also induced by cardiovascular drugs in vivo. Aldh1a1, Acot3, 
Apoa4, Crat and Pklr were only modified in vivo but not in vitro, while PPAR related 
genes Hmgcs2, Cyp4a2, Cyp4a3 were induced in vitro only (Table S3.6). The clustered 
CNS drugs, imipramine, iproniazid and amitriptyline did not share any common 
dysregulated genes in vivo and in vitro (Table S3.8).  
Additional clusters also reflect common drug targets. For instance, caffeine and 
theophylline target adenosine receptor antagonists; diclofenac, ibuprofen and naproxen 
target Ptgs1/Ptgs2; enalapril and captopril interact with angiotensin I converting enzyme 
(Ace); clomipramine and amitriptyline share multiple targets such as neurotransmitter 
transporter (Slc6a2 and Slc6a4) and 5-hydroxytryptamine receptor 2A (Htr2a); and 
clofibrate, benzbromarone and fenofibrate target PPARA. 
There are also some sub-clusters reflecting common hepatotoxicity as for the in vivo data, 
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such as the clusters of indomethacin and clofibrate, of disulfiram and quinidine, and of 
carbon tetrachloride and naphthyl isothiocyanate. The first cluster shows increased some 
of the same gene expressions of PPAR signaling pathway as the in vivo data (e.g. Acot1, 
Acot2, Angptl4, Cyp4a2, Cyp4a3, Ehhadh and Pdk4). The second cluster also shows 
dysregulation of Crct1, Cyp1a1 and Tcp11l2, and the last cluster also induced genes 
associated with MAPK signaling pathway such as Hspa1a, Hspa1b, Hspb1 and Il6 (Table 
S3.9).  
3.4.3 Comparison of in vivo and in vitro gene expression 
In in vivo assay system, all 131 compounds changed expression of at least one gene at 
each dose level and time point while in in vitro rat hepatocytes 28 compounds changed 
none. In some instances, this could have a profound impact on interpretation of results. 
For example, considering genes modified by PPARA ligands (Table S3.6), seven of the 
fatty acid beta oxidation-related genes were commonly induced in vivo rat liver and in 
vitro rat hepatocytes by at least five agents, whereas genes responsible for cell 
communication (Acta1) and cytochrome P450 (Cyp1a1, Cyp4a2 and Cyp4a3) and PPAR 
signaling pathways (Hmgcs2, Mmp1) were altered in vitro rat hepatocytes but not in vivo 
rat liver. There are no overlapping genes dysregulated by three drugs of the clustered CNS 
drugs, imipramine, iproniazid and amitriptyline between in vitro rat hepatocytes and in 
vivo rat liver (Table S3.8). With the treatments of cisplatin and carboplatin from the 
alkylating cluster, Aldh1a1, Ccng1, and the selenium pathway genes HbaA2, Hba1, Hba2, 
and Lox, Rt1Ce5, Rt1Ec2 were commonly changed in vivo rat liver but not in vitro rat 
hepatocytes, while Aif1, C1qa, Cd48, Cxcr4, Gja1, Marcks, Rgs4 and Slc4a11 were 
exclusively changed in vitro rat hepatocytes (Table S3.10). 
Expression changes in vitro thus might not always reflect the situation in vivo. To quantify 
this, we computed a simple measure of gene expression similarity and studied the 
differences between the in vitro rat hepatocytes and in vivo rat liver expression signatures 
(Figure 3.8). The most similar signatures were those for clofibrate where twelve genes 
show a similar behavior out of 105 genes changed in vivo rat liver and 29 in vitro rat 
hepatocytes, of which ten are clearly involved in PPAR signaling and fatty acid 
metabolism. 
Similarities between the same compound when compared across in vivo rat liver and in 
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vitro rat hepatocytes (Figure 3.8 (a)) are higher than between different compounds and 
this is also generally true when comparing signatures (at different time points) within in 
vivo rat liver (Figure 3.8 (b)) and within in vitro rat hepatocytes (Figure 3.8 (c)) 
separately. However, there are many compounds for which similarity when comparing 
signatures with themselves (in vivo versus in vitro) is as low as that when comparing with 
other compounds. 
All of these plots suggest that there is a limited general correlation between gene 
expression alterations induced by rat liver in vivo and in cultivated hepatocytes. However, 
certain key genes modified in vitro might be reliably used to predict the changes in vivo. 
For example, numerous pathways such as focal adhesion, adipocytokine/PI3K-Akt/NF-кB 
signaling, cell cycle related to inflammatory responses and cell growth were initiated by 
penicillamine stimulation at 29 days in vivo (Figure 3.9(a)). Among those, adipocytokine 
and PI3K-Akt signaling pathway were activated by genes of Cd36 and Cxcl1, respectively. 
These pathways lead to inflammatory responses and accordingly the detoxification gene of 
metallothionein (Mt2A) induced and genes of Onecut1 and Rrm2 involved with cell cycle 
reduced. Interestingly, all genes associated with the inflammatory state significantly 
changed by penicillamine at 24 hours in vitro were contained in those pathways although 
such genes (Ccna2, Ccnb1, Igfbp3, Dusp9, and Rrm2) were all suppressed, which may 
reflect the similar mechanism but a different cell responses possibly because of dose 
differences, i.e., high concentration penicillamine might already induce toxicity in vitro 
(Figure 3.9(b)). 
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Figure 3.8 Histogram of gene expression similarities from all-by-all compound comparison. The column 
highlighted in red shows the frequency which counts for gene expression values are at least 2 fold changed 
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induced by any two same compounds, and the blue column shows the frequency of that induced by any two 
different compounds. (a) occurrence of the gene expression similarities between in vivo and in vitro (b) 
occurrence of gene expression similarities between in vivo and in vivo (c) occurrence of the gene expression 
similarities between in vitro and in vitro 
 
Figure 3.9 Network structure presentation of fold change. (a) The fold change data of rat liver at 29 days 
after penicillamine treatment are presented, where red and blue indicate up (fold change > 2, p < 0.01) and 
down (fold change < -2, p < 0.01), respectively. (b) The fold change data of rat hepatocytes at 24 hours after 
penicillamine treatment are presented, where red and blue indicate up (fold change > 2, p < 0.01) and down 
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(fold change < -2, p < 0.01), respectively. 
3.4.4 Comparison between Rat & Human data 
We studied microarray data for drug-treated human and rat hepatocytes in vitro with the 
purpose of understanding how well human cell responses to chemicals can be inferred 
from rat. The cluster tree of gene expression also indicates that several chemicals with 
similar ATC code gather into small subclasses (Figure 3.10). However, only 9.8% of 
these genes were common for human and rat hepatocytes and 11% were conserved 
between in vitro human hepatocyte and in vivo rat liver.  
None of the genes related to the beta oxidation of fatty acids were changed in human 
hepatocytes (Table S3.6), which agreed with the previous observations that PPARα 
ligands do not cause peroxisome proliferation in humans (Harmon et al., 2011). Similarly, 
the changes of genes treated with compounds belonging to CNS agents, musculoskeletal 
drugs, antineoplastic and immunomodulating  
 
Figure 3.10 Dendrogram showing the clustering of 38 compounds based on gene regulation in vitro human 
hepatocytes. The enriched biological features are labeled on the tree. 
agents were not apparent in human hepatocytes (Table S3.8, S3.7, S3.10), but genes 
ANLN, CDC2, NCAPG, RRM2 and TOP2A involved in the cell cycle were consistently 
down-regulated by alimentary tract drugs in human hepatocytes (Table S3.11), which 
might indicate that these chemicals have induced toxicity in human hepatocytes. 
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3.4.5 Liver and kidney gene expression comparison in vivo 
To test how tissue selection affects the gene expression patterns of chemicals, we 
compared gene expression data obtained from liver and kidney.  Unsurprisingly, 
compound administration resulted in relatively few gene expression changes at any time 
point in the kidney compared with the liver. Increases in the expression levels of 
numerous genes related to immune response were more pronounced in rat kidney than 
liver in vivo for allopurinol, gentamicin, cephalothin, enalapril or triamterene. Elsewhere, 
the class of antineoplastic and immunomodulating agents occupies a large part in the 
cluster tree of gene expression (Figure 3.11) which universally elevated expression of 
renal damage genes, e.g., Snca, Cdkn1a and Havcr1 (Table S3.12). These differences 
suggest that gene expression profiling involving multiple tissues might be helpful in 
identifying the target tissues of chemicals with unknown mechanisms of therapy and 
toxicity. 
 
Figure 3.11 Dendrogram showing the clustering of 20 compounds based on gene regulation in vivo rat 
kidney. The enriched biological features are labeled on the tree. 
3.4.6 Agreement between gene expression profiles and chemical features 
3.4.6.1 Correlation of gene expression patterns and molecular descriptors 
We studied the impact of a set of basic chemical descriptors of its structure and function 
across 98 compounds on the in vivo gene expression. The key assumption is that the 
chemical properties as encoded in the descriptors representing the lipophilicity of 
compounds impacts on the specific patterns of gene expression. In more specific terms, 
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the drug metabolizing genes Aldh1a1, Aldh1a7, Cyp2b1, Abcc3, Akr7a3 and Ces2l were 
the top six genes most often up-regulated by the 80 lipophilic agents in vivo, whereas the 
top six cell proliferation genes (Cdk1, Cdkn3, Rrm2, Onecut1, Stac3 and Cish) were 
mostly up-regulated in expression by 15 hydrophilic compounds and are all involved in 
the anti-inflammatory pathway (Table S3.13). This agrees broadly with the notion that 
lipophilic and hydrophilic drugs differ in their clinical capabilities. For example, lipophilic 
xenobiotic compounds are typically converted/activated by drug metabolizing enzymes in 
phase I (Hodgson and Goldstein, 2001; Iyanagi, 2007) and then conjugated with 
endogenous hydrophilic molecules (sugars, glutathione) resulting in hydrophilic forms by 
Phase II enzymes (Iyanagi, 2007), while the hydrophilic xenobiotic containing functional 
groups can directly enter Phase II (Eapen et al., 2007). 
3.4.6.2 Correlation of gene expression similarity and molecular similarity 
We computed the pairwise correlation between Jaccard coefficient of the gene expression 
fold change in vivo or in vitro and their corresponding molecular similarity, separately. 
We then fit linear model with the similarity of the gene expression as the independent 
variable and the similarity of the chemical structures as the dependent variable. 
Interestingly, the molecular similarity (Tanimoto, which is also a Jaccard index) of the 
chemicals is not correlated well with similarity in gene expression (Figure 3.12), though 
most points correspond to low similarities of both gene expression and molecular structure. 
There are individual instances showing higher gene expression similarity with lower 
molecular similarity and higher molecular similarity with lower gene expression similarity 
(Table S14). Virtually all instances of highly similar gene expression with no molecular 
similarity correspond to PPARα ligands (with increased lipid metabolizing genes). It is 
well known that PPARα ligands can lack any apparent molecular similarity (Harmon et al., 
2011), and only the fibrates have clearly similar molecular features (Figure 3.13). 
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Figure 3.12 Correlation of similarity between gene expression and molecular structure. 
 
 
Figure 3.13 Some common fragments found in compounds with very similar gene expression patterns in rat 
liver. 
3.4.6.7 Correlation of gene expression and chemical fragments 
The fragment matrix (98 compounds x 1332 fragment identifiers (> 8 non-hydrogen 
atoms)) shows a projection of fragments into a reduced chemical space. We used PCA to 
reduce these 1332 fragments to 135 loadings on the first two principal components. The 
plot of the first two components (Figure 3.14) shows a separation of cardiovascular, 
musculoskeletal, and CNS drugs and a cluster of antineoplastic and immunomodulating 
agents.  
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The most prevalent fragments in each class are listed in Figure 3.15. Acetanilide 
substructure containing compounds (first cluster), including diazepam, diltiazem, 
acetaminophen, acetamidoflurorene and phenylbutazone, commonly induced drug 
transporters (Abcb1a, Abcc3) and drug metabolizing genes (Akr7a3, Aldh1a1, Cyp2b1, 
Sult2al1 and Ugt2b1). Another two acetanilide containing compounds, bucetin and 
phenacetin, induced (in addition to these drug-metabolising genes) L-serine biosynthesis 
genes such as Phgdh (phosphoglycerate dehydrogenase) and Psat1 (phosphoserine 
aminotransferase), which were reported to be related to cell proliferation (Sun et al., 2015). 
Compounds containing the 2-(2-methylphenoxy) moiety (ethanamine, mexiletine and 
moxisylyte), all up-regulated genes in the estrogen and PI3K-Akt signaling pathways. 
Chlormezanone, ketoconazole, chlorpheniramine, haloperidol and furosemide contain a 
scaffold of 4-chlorotoluene (second cluster) and commonly dysregulated cell proliferation 
related genes, including Cish and Gadd45b. Furan-2-carbaldehyde-hydrazone containing 
compounds (dantrolene, nitrofurazone and nitrofurantoin) (third cluster) all increased drug 
transport and metabolism genes Abcc3 and Akr7a3 and decreased the cell proliferation 
gene Rrm2. 
 
Figure 3.14 Fragment space of chemicals defined by the first two factors from an analysis of 1332 
substructures. Colors highlight different clusters of drugs (red - first cluster – cardiovascular drugs; yellow - 
second cluster – musculoskeletal drugs; green – third cluster – CNS drugs; blue – fourth cluster - 
antineoplastic and immunomodulating drugs)  
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                       acetanilide                      4-chlorotoluene             furan-2-carbaldehyde 
Figure 3.15 Most prevalent fragments found in three clusters of chemicals. 
3.4.7 Predicting pathology signatures based on chemical fragments and gene 
expression data 
3.4.7.1 Correlation analysis between gene expression and pathology signatures 
We used TG-GATES histopathology data of liver and kidney to build matrices containing 
131 compounds and 31 pathological terms for in vivo rat liver, 24 for in vivo kidney, and 
31 for rat hepatocytes (mapped from in vivo data). Each compound profile has elements of 
1 or 0 denoting whether or not it is associated with each pathological term. To encode the 
gene expression profiles of 131 compounds, genes dysregulated by at least four 
compounds at any time points and any dose levels were considered (FC > 2, or FC < -2, 
and p < 0.01). Each compound was thus represented by 853, 396 and 966 binary values for 
liver, kidney and hepatocytes.  
Gene expression and histopathological records were randomly split into a training set 
(80%) and a test set (20%). SCCA was trained by 5-fold cross-validation using R 
(Pauwels et al, 2011). The performance was evaluated by ROC curves (Figure 3.16 all 
predictions merged into one curve). SCCA was computed using parameters of c1 = c2 = 
0.04 (penalty) and m = 20 (number of components). The resulting AUC scores are 0.7883, 
0.731, and 0.7545. The curves suggest that there is capable predictive power of using these 
data.  
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Figure 3.16 ROC curves for the 5-fold cross-validation comparing the performance of SCCA on in vivo rat 
liver, kidney and in vitro rat hepatocytes 
We examined the weight vectors for chemical fragments and pathological outcomes in 
SCCA to extract the relationship between two datasets. Table S3.15 shows the weight 
vectors of canonical components in SCCA and most of the elements in the weight vectors 
are zero, implying that SCCA can select a small number of gene-sets or pathologies as 
informative. A few sets of genes and pathological records in the canonical component with 
correlation coefficient larger than 0.6 were extracted using SCCA. Each component 
consists of an association of a set of genes and one pathological term. For each component, 
two lists of compounds are provided, one containing compounds with a high score for the 
associated genes, and the other containing compounds with a high score for the associated 
pathological observations. Table S3.16, S3.17, S3.18 show the selected correlations 
between genes and pathological observations for liver, kidney and hepatocyte experiments, 
separately. 
Several of these components show plausible biological mechanisms. For instance, 
component 2 corresponds to “inflammation” and includes a set of up-regulated genes, 
such as Il7, Ccl21, Stat3, Dsc2 and Slc13a5 that are involved in inflammation pathways in 
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the liver dataset. The top ten compounds scored by this cluster belong to the same ATC 
inflammation category (Table S3.16). This finding agrees with our earlier conclusion that 
gene expression patterns tend to reflect the MoA of drugs rather than toxicity per se. 
3.4.7.2 Correlation analysis between chemical fragments and pathological signatures 
for in vivo liver 
31 histopathological terms for 52 compounds were extracted from TG-GATEs and 25 
chemical fragment contained by those compounds were defined by the CCQ 
fragmentation method (ChemAxon, https://www.chemaxon.com), which leaves functional 
groups of molecules intact so that they are better reflections of potential mechanism. Each 
compound was represented by a 31 dimensional binary profile and a 25 dimensional 
binary profile whose elements encode for the presence or absence of each of the 
pathological terms or chemical fragments. Data were randomly split into a training set 
(80%) and a test set (20%). SCCA was trained by 5-fold cross-validation. The resulting 
AUC score is 0.6108 using parameters of c1 = c2 = 0.04 (penalty) and m = 20 (number of 
components).  
A set of fragments and pathological records in the canonical components with a 
correlation coefficient larger than 0.7 were extracted (Table S3.15). For instance, 
component 1, with highest canonical correlation (0.771), associates the substructure 2-
aminopyridine to a list of pathological indications of hepatotoxicity such as alteration, 
anisonucleosis, hemorrhage and vacuolization. The 2-aminopyridine moiety, defined as 
structural alert of hepatotoxicity in some antibacterial drugs due to its ability to form 
reactive metabolite (Stepan et al., 2011). This cluster shows alterations in genes related to 
anisonucleosis, including Id1 (inhibitor of DNA binding 1), Tp53inp1 (tumor protein p53 
inducible nuclear protein 1) and Unc5b (unc-5 homolog B), which are all involved in 
apoptosis and cell death.  
3.5 Conclusion and discussion 
The first major finding in this chapter is that much of toxicogenomics results reflect the 
underlying mechanism of drug action, and indeed overall similarities in expression 
patterns seem to be more related to drug mechanism than underlying similarities in 
toxicology. This is somewhat surprising as the target tissues (liver, kidney) are not 
Chapter III 
 
68 
traditionally considered to be targeted by many of the drugs considered (e.g. 
acetaminophen, etc.). For some compounds, we also find only a weak effect on gene 
expression, which could reflect dosing problems as was reported previously There are, of 
course, exceptions to this in our own analyses (Figure 3.1), and indeed in the general, well 
established utility of gene expression analyses to uncover new toxicity biomarkers. For 
instance, the gene kidney injury molecular 1 (Kim1 or HAVCR1 in humans) is highly 
evident in the TG-GATES (Table S3.12) and other expression datasets as an indicator of 
kidney toxicity (Ichimura et al., 1998; Kondo et al., 2009), and many other known and 
potentially novel biomarker candidates are present within these and other expression data. 
Nevertheless, our overall findings have some important implications for methods to 
predict toxicity, suggesting a need to account for (or remove) mechanistic contributions to 
expression profiles before deriving multi-gene predictors. 
The second major observation is that there is limited overlap between in vivo and in vitro 
studies when considered across this large set of compounds. The notion that cell lines are 
poor mimics of mammalian tissues is certainly not new, but our results provide a 
systematically derived degree of similarity for guidance. Additionally cell lines, such as 
3D cell cultures that are believed to be a better mimic of human organs that 2D cultures 
(Fey and Wrzesinski, 2012) will likely improve upon the general picture we have seen 
here. The overlap among different assay systems (rat in vivo, rat in vitro and human in 
vitro) is also endpoint dependent. For example, we found that PPARα ligands such as 
ibuprofen, fenofibrate, and clofibrate consistently influenced lipid metabolism in all three 
systems. When Liu et al. limited their analysis to specific hepatotoxic endpoints, the in 
vitro to in vivo extrapolation potential was improved (Liu et al., 2017). 
Overall, our results suggest that large scale evaluation of gene expression patterns is a 
useful tool for predicting mechanisms of chemotherapeutic agents and toxicity of 
unknown chemicals. It is apparent that each compound produces its own, unique 
expression profile and that similarities in profiles between compounds can indicate 
similarities in therapeutic and toxic mechanism. Almost certainly, a systematic analysis 
combined with biological and chemical features is essential to make accurate assessments 
of drug mechanism and toxicity based on similarity of gene expression profiles. Several 
studies have provided considerable sets of expression signatures to help decipher drug 
mechanism, toxicity or other biological features (e.g Gray, et al., 1998; Velculescu et al., 
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1999). The more challenging task is to relate chemical features with systemic responses. It 
is not always robust that chemicals with very similar structure have similar 
toxicogenomics profiles. However, some compounds containing the same specific 
substructures show similar outcomes. Therefore, combining chemical structure and 
toxicogenomics may improve the assessment (Low et al., 2011). Our results confirm the 
value of compound-centered view of phenotypes for identifying the effects of chemicals 
on phenotypic outcomes as suggested previously (Duran et al., 2014) and will accordingly 
help efforts to relate chemical structure to biological response. 
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CHAPTER IV: Common, functional mutations in human 
subpopulations potentially causing individual susceptibility to 
toxicities or other pathologies 
4.1 Abstract 
Genetic variants can determine both inter-individual and inter-ethnic differences in many 
physiological processes, including drug efficacy or toxicity, sensory perception, and dietary 
responses. Many differences are attributable to single nucleotide polymorphisms (SNPs) in 
key drug response, metabolism, and sensory receptor genes. In this chapter, we first study 
SNPs in all genes in 2 504 humans uncovered by the 1000 Genome Project to check what 
kinds of genes are frequently the subject of variations in healthy people. Variants are 
enriched in processing like the immune response, sensory perception and drug metabolism. 
We then explore how variants might affect these processes, particularly drug metabolism, 
where we find many common variants likely to alter how individuals react to xenobiotics. 
The results could be potentially used in personalized medicine to define different doses for 
discrete patient populations. 
4.2 Introduction 
Recent years have seen the birth of several additive/metabolite controversies. For example, 
the flavor enhancer monosodium glutamate (MSG) is thought to cause what was once called 
“Chinese restaurant syndrome” (Kwok, 1968). Tryptophan, which is high-content in turkeys 
and eggs, is believed to give rise to tiredness, which is an oft cited reason for fatigue after 
Thanksgiving dinner in the US (Hartmann and Spinweber, 1979). However, systematic 
studies have found nothing significant. One hypothesis is that there are small subsets of 
people that experience such chemical-induced syndromes, but that these fractions are not 
easily detected in trials involving small groups of randomly selected healthy individuals.  
With the increasing availability of “-omics” technologies on the back of the human genome 
project, more and more studies now focus on the study of genetic variation among 
individuals or human populations. The most common genetic variation studied in these 
contexts are single nucleotide polymorphisms (SNPs), defined as mutations changing single 
nucleotides in at least 1% of the human population. They have a key role in genetic changes 
associated with diseases and individual responses to certain chemicals, such as drugs and 
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toxins (Roses, 2000).  
Recent studies of polymorphisms have demonstrated the impact of genetic variation on a 
many common traits. For example, there is some evidence that variations in taste or odor-
perception are associated with polymorphisms in taste or olfactory receptors (Pronin et al., 
2007; Jiang and Matsunami, 2015). For instance, genetic studies have identified that 
variations (e.g., A5T, R247H, R757C) in TAS1R3 are related to the capability of tasting 
MSG (umami) (Chen et al., 2009). Another example is T2R43, where the W35 allele 
enables individuals to taste the bitterness of the plant toxins, aloin and saccharin (Pronin et 
al., 2007). The first clear link between odor perception and genotype was described in 
olfactory receptor OR7D4, where variants cause different responses and/or preferences for 
food (e.g. pork) containing androstenone (Lunde et al., 2012).  
Single nucleotide variations in genes encoding drug metabolizing enzymes (DMEs), drug 
targets, drug transporters and human-leukocyte antigen are considered to be responsible for 
inter-individual differences in drug response (e.g., efficacy, toxic effects) (McLeod and 
Evans, 2001). Many studies focus on the CYP450 gene family, where several variants are 
known to cause primary differences in drug-response (Puga et al., 1997). For example, for 
CYP2D6, there are four major phenotypes of metabolism: extensive metabolizers with two 
functional alleles, poor metabolizers with two non-functional alleles, intermediate 
metabolizers with one functional and one non-functional allele, ultra-sensitive metabolizers 
with one or more alleles improving enzyme activity above extensive metabolizers (Puga et 
al., 1997). Other variants within genes and their relevant substrates have also been studied to 
evaluate drug responses such as: L128R and Y139F in the warfarin resistance enzyme 
VKORC1 (Ma and Lu, 2011), and mutations in KRAS related to resistance to the anti-
EGFR monoclonal antibodies cetuximab and panitumumab (Fakih and Wong, 2010).  
Toxic effects can also result from genetic variants affecting drug 
pharmacokinetic/pharmacodynamic processes. For example, variations in the ryanodine 
receptor gene (e.g. protein change p.C614R) are found to account for susceptibility to 
malignant hyperthermia after anesthetic treatment in more than 50% of cases (Gillard et al., 
1991). The g.C3435T variant in the drug transporter gene ABCB1 produces an adverse 
reaction to anticancer agents and cardiac glycosides (Sheng et al., 2012). Analysis of 
variations in GSTT1 and GSTM1 shows that Alzheimer’s disease patients with deficiencies 
of both genes are more likely to experience hepatotoxicity when treated with tacrine (Roy et 
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al., 2001). Low-dose methotrexate toxicity is often found in patients with the g.C677T 
mutation in the drug target methylenetetrahydrofolate reductase (Spyridopoulou et al., 2012).  
These examples indicate the impact of a few common variants on a common trait. However, 
the entire genetic landscape of inter-individual differences of response to chemicals still 
remains to be systemically elucidated. High-throughput sequencing has contributed to the 
systematic unraveling of thousands of variants potentially disturbing biological systems or 
causing diseases (Kilpivaara and Aaltonen, 2013). However, understanding the genetic 
contribution also requires knowledge of the abundance and distribution of mutations in the 
general population. The 1000 Genomes (1000G) Project Phase 3 (May 2013) has explored 
the spectrum of common human genetic variation by sequencing 2504 individuals from 
various populations (The 1000 Genomes Project Consortium, 2015). An earlier study from 
GlaxoSmithKline provided a comprehensive description of rare variants (MAF ≤ 0.5%) in 
human population by applying sequencing to 202 drug target genes from 14002 individuals 
(Nelson et al., 2012). Meanwhile, several high-throughput computational approaches to 
determine the influence of mutations on protein-ligand interactions have been established 
(Pires et al., 2014; Reva et al., 2011). Recently, we presented Mechismo (Mechanistic 
Interpretation of Structural Modifications) to predict whether mutations are likely to 
enhance or diminish the interactions of protein-protein, protein-nucleic acid and a set of 
protein-ion by calculating the frequency of a given residue in protein-related ligand class, 
which can provide the mechanistic basis of how mutations lead to specific functional 
sequences (Betts et al., 2015). A newer study proposes mCSM-lig, a structure-guided 
strategy for quantifying the influences of mutations on binding of small molecules with 
proteins, which completed the assessment of the effects of mutations on protein-small 
molecule complexes (Pires et al., 2015; Pires et at., 2016). 
In this chapter, we extracted information on genetic variants in the healthy individuals from 
1000 Genomes Project. We sought variations that would be expected to differentiate 
humans by their ability to process chemical molecules by linking the common variants (i.e. 
present in more than 1% population) to small molecules via chemical-protein interactions in 
the Mechismo system. This allowed us to predict/identify how small molecules bind to 
proteins and whether any common SNPs at the binding sites might impact these interactions. 
Some of the changes were predicted by mCSM-lig. We also linked several variants to 
potential individual susceptibility to toxicity for some withdrawn drugs by examining 
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chemical-protein complexes in Mechismo. This study will have applications in the 
understanding of drug response across subpopulations and thus implications for 
personalized or precision medicine. 
4.3 Methods 
4.3.1 Processing Data from 1000G 
1000 Genomes Project Phase 3 (May 2013 sequence freeze) data were mapped to Ensembl 
(Aken et al., 2016) proteins using Variant Effect Predictor (VEP) (McLaren et al., 2016) and 
version 79 of the human genome version GRCh37. This includes 2 504 samples from 26 
human sub-populations in five major population groups: Africa (AFR), the Americas 
(AMR), East Asia (EAS), Europe (EUR), and South Asia (SAS). Each of these populations 
has an associated minor-allele frequency (MAF) and there is a global value (GMAF) that 
spans the entire human population. The dataset also provides, for each individual, 
information about the zygosity of the variant (ie. whether it is absent/wild-type, 
heterozygous or homozygous). VEP provides predictions of the possible severity of a 
mutation according to SIFT version 5.2.2 (Sim et al., 2012) and PolyPhen version 2.2.2 
(Adzhubei et al., 2010). 
4.3.2 Deriving protein altering variants information 
The source of protein altering variants in human proteins imported from the Ensembl 
Variation database (Chen et al., 2010) was downloaded from UniProt (UniProt Consortium, 
2015). It included in total 1 271 699 unique variants. The description of GMAF for a variant 
was mapped from 1000G project. We defined a dataset of common missense (amino acid 
altering) SNPs as those with GMAF ≥ 1%. The frequency distribution of missense variants 
in a protein was defined as the total number of missense substitutions found within it 
divided by the protein length. 
4.3.3 Gene enrichment analysis 
For gene enrichment analysis we used GetGo (http://getgo.russelllab.org),  which performs 
fast enrichment analysis of human gene sets considering pre-computed gene lists of 
different classes (Gene Ontology (Ashburner et al, 2000), Pathways, UniProt diseases, 
Complexes, etc). Enrichment p-values are assigned to each list using a Fisher's exact test 
Chapter IV 
 
75 
and multiple testing corrections. 
4.3.4 Relating chemical molecules to genes 
We ran all the missense variants through Mechismo (mechismo.russellab.org), and 
chemicals at the variation sites were showed or predicted by Mechismo. Mechismo contains 
roughly one million connections between human proteins and connected with chemical 
identifiers in the protein databank (PDB) (Gutmanas et al., 2014) and the confidence of each 
match based on the sequence identity between the UniProt sequence and the protein of 
known structure. It also provided approximately 50000 protein-protein, protein-nucleic acid, 
protein-small-molecule interactions with known 3D structures and several million 
interactions identified by other methods. Since we previously benchmarked the prediction 
accuracy as a function of protein sequence similarity, we could use relatively low sequence 
similarities (Betts et al., 2015).  
4.3.5 Predicting the effects of missense variations 
We used mCSM-Lig to predict the impact of the missense substitutions upon the binding 
affinity of protein for the substrates. This method uses graph-based signature to represent 
the wild-type and chemical environment of a residue to predict the change upon variation in 
Gibb’s free energy of binding or stability (Pires et at., 2016). 
4.4 Results 
4.4.1 Gene function enrichment 
Table 4.1 shows the most enriched Gene Ontology terms and pathways for the set of 1 512 
genes that have (Number of common_SNPs/length) > 0.01. There are four main groups of 
genes, which can also be visualized as a network (Figure 4.1). 
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Table 4.1 The most enriched Gene Ontology terms and pathways 
Term/Pathway 
ID 
Term/Pathway Obs Exp P-value Genes 
Gene Ontology 
GO:0007608 sensory perception of 
smell 
28 10.6 0.01016 GJB4 GNAS OBP2A OBP2B OMP 
OR2D2 OR2S2 OR51B5 OR51B6 
OR51I1 OR51J1 OR51M1 OR5B3 
OR5D14 OR5H1 OR5H14 OR5H15 
OR5H6 OR5I1 OR5K3 OR5R1 
OR5W2 OR6B2 OR8D4 OR8H2 
OR8H3 OR8U1 UGT2A1  
GO:0001580 detection of chemical 
stimulus involved in 
sensory perception of 
bitter taste 
13 2.7 0.01693 CA6 CST1 CST2 CST4 RTP4 
TAS2R19 TAS2R31 TAS2R38 TAS2R4 
TAS2R42 TAS2R43 TAS2R5 TAS2R7  
GO:0045095 keratin filament 27 7.2 9.607x10
-06
 KRT74 KRTAP1-1 KRTAP10-1 
KRTAP10-10 KRTAP10-11 KRTAP10-
3 KRTAP10-5 KRTAP10-6 KRTAP10-
7 KRTAP10-9 KRTAP12-1 KRTAP12-
2 KRTAP12-3 KRTAP2-1 KRTAP2-2 
KRTAP2-3 KRTAP3-2 KRTAP4-1 
KRTAP4-11 KRTAP4-4 KRTAP4-5 
KRTAP4-7 KRTAP4-8 KRTAP4-9 
KRTAP5-5 KRTAP5-9 KRTAP9-6  
GO:0006955 immune response 42 20.0 0.00148 BPI C1QC C8A CCL11 CCL14 
CCL17 CCL25 CCL4L1 CD1E CD276 
CHIA CTSG FCAR FCGR1B 
FCGR3B GBP6 GZMA GZMB HLA-A 
HLA-B HLA-C HLA-DPA1 HLA-
DQA1 HLA-DQA2 HLA-DRB1 IFI44L 
IFITM2 IGHA1 IL1RL1 IL24 IL36A 
IL37 IL4R IL7R KIR2DL1 KIR2DL3 
KIR3DL1 LILRB2 LY75 MS4A2 PRG3 
SBSPON SECTM1 TINAG TLR1 
TLR10 TLR6 TNFRSF14 TRGV3 
TRIM22 XCL1 XCL2  
GO:0030574 collagen catabolic 
process 
20 5.5 0.00434 COL11A1 COL11A2 COL17A1 
COL18A1 COL19A1 COL23A1 
COL2A1 COL3A1 COL4A1 COL4A2 
COL4A3 COL4A4 COL4A5 COL4A6 
COL5A3 COL8A2 COL9A1 COL9A2 
COL9A3 MMP8  
REACTOME Pathway 
R-HSA- antimicrobial peptides 29 6.7 5.470x10
-07 ART1 BPI BPIFA2 BPIFB1 BPIFB4 
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6803157:2  BPIFB6 CHGA CTSG DEFA4 DEFA6 
DEFB108B DEFB116 DEFB119 
DEFB124 DEFB126 DEFB127 
DEFB128 DEFB129 GNLY HTN3 
PGLYRP2 PGLYRP3 PGLYRP4 PI3 
REG3G RNASE7 S100A7A SEMG1 
TLR1  
R-HSA-
211859:1 
biological oxidations 32 14 0.00961 ACSM2A ACSM5 AKR7A2 AKR7A3 
AKR7L CBR3 CES1 CYP1B1 CYP2A7 
CYP2F1 CYP2W1 CYP3A43 CYP4A22 
CYP4B1 CYP4F12 FMO2 GLYATL3 
GSTA2 GSTM1 GSTM4 GSTM5 
GSTZ1 MTRR NAT2 NQO2 SULT1A2 
TBXAS1 UGT1A5 UGT2A1 UGT2B10 
UGT2B11 UGT2B28 
R-HSA-
420499:3 
Class C/3 
(Metabotropic 
glutamate/pheromone 
receptors) 
12 2.6 0.01608 TAS1R1 TAS1R2 TAS2R19 TAS2R20 
TAS2R31 TAS2R38 TAS2R4 TAS2R42 
TAS2R43 TAS2R5 TAS2R7 TAS2R9 
 
As might be expected, many genes are enriched in mutations in healthy people. Olfactory 
and taste receptors, drug metabolism, immune response, skin, hair and nails constituent 
(collagen and keratinization) are the functions enriched in the gene set that has more SNPs. 
The most visible phenotypic variations in human - skin, hair and nails are remarkably 
variable. Pigmentation is a polygenic cause of this observation (Wilde et al., 2014). The 
high diversity might be a result of selection pressures associated with the adaption to an 
agriculturalist diet, and influence of UV radiation (UVR) (Wilde et al., 2014). 
Odorant receptors and taste receptors belong to a specific sub-class of GPCRs, with seven 
trans-membrane helices, and reside in the membranes of olfactory neurons, interestingly 
where one neuron expresses just one specific receptor (Mori and Sakano, 2011). It has been 
reported that olfactory receptor genes are diverse and rapidly evolving (Buck and Axel, 
1991). For example, Mainland et al. (Mainland et al., 2014) found that 63% of the odorant 
receptors had genetic polymorphisms that likely altered in vitro receptor functions. On 
average, 30% of odorant receptor alleles were functionally different in two individuals. 
Residues likely altering functions were found all over the protein (i.e. not restricted to any 
domain). They also computed the odds that a residue changed function in their arrays did 
not associate with evolutionary conservation, but deviated from neutral evolution (Mainland 
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et al., 2014). Hoover et al. identified putative evolutionary adaptive trends of smell 
perception by analyzing the geographic distribution of variants in OR7D4 among 2224 
individuals from 43 populations. They concluded that the enormous functional variability 
among human sense of smell might be ascribed to the specific population selective pressure 
to local environments or diet (Hoover et al., 2015). Although the low Ka/Ks ratio showed 
that there were more synonymous than nonsynonymous substitutions, the high frequency of 
variants and high fixation scores for the deleterious alleles suggested positive selection 
(Hoover et al., 2015). Another explanation could be attributed relaxed functional constraints 
(for example in the specific example of OR7D4), which would result in the accumulation of 
mutations on odorant receptor genes, ultimately, leading to either loss of function or the 
emergence of new functions over time (Mainland et al., 2014). 
Taste receptors are also GPCRs, which are responsible for five main tastes (i.e., sour, sweet, 
bitter, salty, and umami). There are numerous differences in taste sensation across human 
populations, owing to rapid evolution and high polymorphism in taste receptors (Foster et 
al., 2014). Out of the five tastes, interestingly, 24 human T2R (taste 2 receptor) genes 
detecting the bitter taste have been found in our study, significantly more than the genes 
perceiving other tastes. This could be explained by the importance of the bitter perception 
which enables human to better avoid potentially harmful or toxic substances (Montmayeur 
and Matsunami, 2002; Shi et al., 2003). Furthermore, variations in human T2R genes are 
more prevalent in humans than in other mammals, suggesting that the relaxed selective 
constraint for the T2R genes has been working in human populations. Supporting this, it has 
been shown that the efficiency of perceiving bitter taste has been weakened in the human 
lineage (Niimura and Nei, 2006). In addition, the high-frequency genetic polymorphisms in 
odorant and taste receptors in the human genome are ascribed to their cooperation in flavor 
perception, suggesting they have evolved together in vertebrates (Hasin-Brumshtein et al., 
2009). 
Immune system genes such as HLAs (human leukocyte antigens), KIRs (Killer-cell Ig-like 
receptors), and TLRs (Toll-like receptors) are ranked among the most variable in the 
genome (Trowsdale and Parham, 2004). Most of the variations are associated with binding 
of peptides from pathogens to the grooves of MHC (major histocompatibility complex) I 
and II molecules (Trowsdale and Parham, 2004). Polymorphism is exploited by those genes 
in order to conflict with a large number of different pathogens. The wide variation is most 
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likely a result of a selection for highly increasing the defense potential and therefore reduces 
the risk that the whole population will be eliminated by a pathogen (Davis, 2014). 
Drug metabolizing enzymes (DMEs) metabolize a wide range of drugs and naturally 
generating toxins in the environment. The evolution of DMEs occurred after the animals 
moved to the land and encountered the plants there (Nebert, 1997). The new environmental 
chemicals might be responsible for shaping this high diversity of DMEs (Nebert, 1997). For 
example, the DME genes produced polymorphic enzymes that can enable or diminish the 
responses to plant diet (Ingelman-Sundberg et al., 1999). SNPs of enzyme metabolizing 
novel environmental chemicals caused changes in function of the enzyme to give an 
individual a positive or negative evolutionary selection (Janha et al., 2014). For example if 
the cytochrome P450 enzyme eliminated the toxic chemical, a gain-of-function allele might 
be positively selected. By contrast if the enzyme transformed a non-toxic precursor into a 
toxin, an allele with poor enzyme activity might be selected (Janha et al., 2014). 
4.4.2 Variants at the chemical binding sites 
Interestingly, many of these variants are at sites predicted or known to interact with 
chemicals. Such variants are likely to induce direct functional effects on these proteins. For 
example, the Y402H mutation in CFH/CFHR proteins was identified to increase the risk of 
age-related macular degeneration by altering the binding affinity to heparin sulphate (HS), a 
polysaccharide present on the cell surface (Langford-Smith et al., 2014). Several SNPs 
occurring within a distance of 5Å from their chemical ligands that might result from 
perturbations were identified by Mechismo system (Table 4.2).  
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Figure 4.1 Gene function enrichment map for genes with more variations. Node size represents the 
number of genes with many variations within the enriched gene-set. Edge size represents the number of genes 
that overlap between two gene-sets connected. Highly redundant gene-sets are grouped together as clusters, 
and groups of functional related gene-sets are manually circled. 
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Table 4.2 Variants at the chemical binding sites 
Uniprot 
entry/variant 
Protein Site Chemical 
Q31610/L133F HLA-B L133F fucose 
Q31610/E176V HLA-B E176V fucose 
Q29974/Q99E HLA-DRB1 Q99E fucose 
Q29974/V114A HLA-DRB1 V114A fucose 
O60449/E331D LY75 E331D fucose 
P04439/A174V HLA-A A174V 2-amino-4-ethyl sulfanyl butyric acid 
P01906/R87T HLA-DQA2 R87T acetamidomethylcysteine 
P15812/L182Q CD1E L182Q N-Glycoloylganglioside GM2 
P24071/D209N FCAR D209N Alpha-GalCer (C20:2) 
P04439/H175R HLA-A H175R N-hexacosanoylisoglobotriaosyl ceramide 
P30480/L133F HLA-B L133F C12:0-di-sulfatide 
P04439/G103R HLA-A G103R glucose monomycolate 
P23141/Y366C 
P23141/M361V 
P23141/A93V 
CES1 Y366C 
M361V 
A93V 
tamoxifen 
P09210/R13Q 
P09210/D42G 
P09210/V55L 
P09210/P110S 
P09210/S112T 
GSTA2 R13Q 
D42G 
V55L 
P110S 
S112T 
etacrynic acid 
 
Several variants at the binding sites of ligands and human MHC I and MHC II were 
predicted by Mechismo (Table 4.2). A study suggested that small carbohydrates (e.g. fucose) 
attach to the linkers (lipids, e.g. acetamidomethylcysteine, 2-amino-4-ethyl sulfanyl butyric 
acid) to fulfill the requirements of α/β and γ/δ TCR (T-cell receptor) antigen binding, as part 
of glycopeptide and carbohydrate-specific T cell responses (Speir et al., 1999).  
The four long chain glycolipids, N-Glycoloylganglioside GM2, Alpha-GalCer (C20:2), N-
hexacosanoylisoglobotriaosyl ceramide and C12:0-di-sulfatide are α-Galactosylceramide (α-
GalCer)-like antigens of type I natural killer T (NKT) cells which initiate immune responses 
during disease by modulating cell signal transduction events (Fujii et al., 2003). Most NKT 
cells are activated by CD1d-glycolipid complex through their CDR2β and CDR3α loops 
which recognize glycolipid antigens (López-Sagaseta et al., 2012). The other human MHC 
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class I-like protein CD1b shows the capability of accommodating broader range of 
differences in lengths (up to 80 carbons) of acyl chains of glycolipids. For example, the 
structure of CD1b complex reported in Batuwangala’s study presented longer acyl chain 
lipids (e.g., glucose monomycolate) occupying the whole part of interlinked channels 
(Batuwangala et al., 2004).  
SNPs at the drug binding sites are often essential determinants of inter individual 
differences in drug response (Langford-Smith et al., 2014), and we identified several of 
these. For example, the xenobiotic processing and metabolizing enzyme carboxylesterase 1 
(CES1) was found to bind to the breast cancer drug tamoxifen (Mésange et al., 2002). In 
Fleming’s drug-CES1 complex structure, tamoxifen bound with eight active site residues 
within the catalytic pocket via hydrophobic contacts (Fleming et al., 2005). The triphenyl 
moiety of tamoxifen fits well in the pocket, with two of the rings connecting with Leu388 
and Phe101 (Fleming et al., 2005). According to mCSM-lig, the mutations A93V, M361V, 
Y366C at the active site cavity are predicted to lead to a destabilizing in affinity for 
tamoxifen and the human CES1 ((PDB ID: 1YA4)) -0.117 log(fold change), -0.518 
log(affinity fold change) and -0.736 log(affinity fold change), respectively. 
Ethacrynic acid (EA) is a potent loop diuretic drug used to lower high blood pressure by 
inhibiting glutathione S-transferases (GSTs) (Somberg and Molnar, 2009). It is a 
phenoxyacetic acid derivative with a ketone moiety and a methylene group in the side chain. 
GSTs catalyze the reaction of the methylene group with glutathione (GSH) to form the 
active form - glutathione conjugate (Ploemen et al., 1993). The complex structures of alpha-
class GSTA1-1 with EA and EA-GSH have been reported (Cameron et al., 1995). The EA 
moiety binds with GST via the dichlorophenoxy group in van der Waals contact with Gly14 
and Phe10, Leu107, Leu108, Val111, Met208 and Phe222. The carboxylate oxygens contact 
with three hydrogen interactions, one with Gly14 and two with water molecules. One has 
hydrogen bonds to the amino nitrogen of Arg13 and the carbonyl oxygen of Pro207. In the 
structure of EA-GSH complex, one of the carboxylate oxygens has two hydrogen bonds, 
one with the carbonyl oxygen of Val55 and the other one with the amino nitrogen of Val55 
through a water molecule (Cameron et al., 1995). Site-directed mutants of R13Q, V55L, 
P110S and S112T are within bonding distance may have effects on the catalytic properties 
of the enzyme. In mCSM-lig, V55L and P110S are predicted to destabilized by -0.715 
log(affinity fold change) and -0.047 log(affinity fold change), separately. 
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4.4.3 Influences of variations on toxicity responses 
Genetic variations in drug metabolizing genes could also lead to toxicity and thereby to drug 
withdrawal or discontinuation in specific populations. We extracted interactions of eight 
withdrawn drugs with their targets and metabolizing enzymes (or homologous proteins) 
from Mechismo to predict mechanistic consequences (e.g., toxicity) for variations (Figure 
4.2). 
Bromoergocryptine was one of the ergot alkaloids acting as the dopamine receptor agonist 
for treating prolactin secretion, type II diabetes, and Parkinson disease. In vivo experiments 
have found that bromoergocryptine is primarily oxidized by CYP3A4 near the heme iron 
with its tripeptide moiety. Two particular residues, Arg212 and Thr224, have been observed 
to sustain their binding conformation where Arg212 directs bromoergocryptine to approach 
to the heme and Thr224 binds to N1 atom of bromoergocryptine by an H-bond 
(Sevrioukova and Poulos, 2012). By searching Mechismo, an amino acid substitution, 
R246H in CYP4F22 with 26.53% sequence similarity to CYP3A4 was found at the interface 
that might influence the drug response. It was reported that bromoergocryptine was 
withdrawn from the market in the USA due to its neurological toxicity (Liu et al., 2013). 
Troglitazone was one of the bile salt export pump potent inhibitors, but troglitazone-induced 
hepatocellular injury led to its withdrawal from the market. It contained the structural alert 
4-ethylphenol which could be activated to form adducts with GSH and induced GSH 
depletion in hepatocytes (Lang et al., 2007). The co-crystallized structure of troglitazone-
CYP2C8 showed that the chromane ring approached to the heme iron, and the 
thiazolidinedione group was closer to the C’ end of chain B. Arg241 on helix G and Asn204 
on helix F donated two hydrogen bonds to the two carbonyl oxygens of the 
thiazolidinedione ring, and Val296 and Glu300 on helix I donated two hydrogen bonds to 
the phenolic oxygen. The ether oxygen of 4-ethyphonel at the middle part of troglitazone 
was hydrogen-bonded to Ser103 on helix B (Schoch et al., 2008). Mechismo identified a 
substitution T298M (in 0.7% of South Asians) at the interface of troglitazone and CYP2W1 
(with 24.26% sequence similarity to CYP2C8) which might impact catalytic activity. 
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Figure 4.2 Interactions of eight withdrawn drugs with their structural alerts and targets/metabolizing enzymes 
present how SNPs on the interface impact the binding activity, leading to drug toxicity 
Another substrate of CYP2C8, isotretinoin, was prescribed as severe acne treatment, 
binding to its enzyme by hydrogen bonds between acetic acid moiety and Asn204 and 
Arg241 (Schoch et al., 2008). The movement of Arg241 from outside of the cavity to inside 
Chapter IV 
 
85 
offered a strong and charge-stabilized hydrogen bond with the acetic acid of isotretinoin. 
The changes of I202M, with a frequency of 0.1% in European people and none in other 
populations, was seen in Mechismo might impact the binding event. Isotretinoin was 
withdrawn from the Italian market due to its effect on male reproduction (Alli and 
Yorulmaz, 2015).  
Tolrestat is one of the aldose reductase inhibitors which was approved for the control of 
diabetes but was withdrawn from the market due to its toxicity. Tolrestat bound crystal 
structure of AKR1B10 showed that the catalytic sites contained Tyr49, His111, NADP+, 
and Trp112, of which Tyr49 and Trp112 donated hydrogen bonds to acetic acid group of 
tolrestat. It was observed from Mechismo that near the active site, there was a substitution 
Q114Ter which could affect the conformational changes of AKR1B10 with ligand binding. 
This might result in the formation of induced cavity in AKR1B10, leading to a broad ligand 
specificity (Shah et al., 2012). 
Acetylsalicylic acid (aspirin) is a nonsteroidal anti-inflammatory drug, but was withdrawn 
from British marketplace due to hepatic and neurological toxicities (Aronson, 2004). 
Acetylsalicylic acid can be oxidized to acetylsalicylic acid free radical by peroxidase 
enzyme (e.g., eosinophil peroxidase (EPX)) (Singh et al., 2010). Acetylsalicylic acid bound 
to EPX by forming one hydrogen bond with a heme iron, which in turn generated two 
additional hydrogen bonds with Gln105 and His109. Two atoms of the acetic acid moiety 
formed other hydrogen bonds with Phe422 and Gln423. It is proposed that acetylsalicylic 
acid is balanced favorably at the active site of the peroxidase (Singh et al., 2010). Compared 
with other EPX inhibitors, the interactions of Phe422 and Gln423 with the acetic acid are 
unique, and suggest possible insights into the mechanism of acetylsalicylic acid toxicity 
(Singh et al., 2010). The substitution F237I (PDB: 2qqt) found in Mechismo could interrupt 
the interaction of acetylsalicylic acid and EPX. 
Indometacin is also a nonsteroidal anti-inflammatory agent used to reduce pain, fever and 
swelling from inflammation and was withdrawn in Germany due to gastrointestinal toxicity. 
The complex of indometacin bound human serum albumin (HSA) showed that the acetic 
acid group binded to Arg218 by a salt bridge, and chlorobenzoyl group lied at the bottom of 
the cavity, thereby the substitution of H222N (approximately 0.1% of the European 
populations) found in the binding sites of alpha-fetoprotein (AFP, 41.13% similarity to 
HSA) might generate protein causing drug binding defects (Ghuman et al., 2005).  
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Oxyphenbutazone and phenylbutazone are potent nonsteroidal anti-inflammatory drugs but 
are associated with liver damage (Kirkland and Fowler, 2010). The potential liver toxicity 
mechanism was illustrated in two studies (Stepan et al., 2011; Kim et al., 2016).  
Specifically, most drugs containing structural alert aniline can undergo metabolic activation 
leading to the generation of reactive oxygen species.  These activate the antioxidant 
response element and PPAR gamma signaling pathways, and disrupt human tyrosyl-DNA 
phosphodiesterase 1 and thyroid receptor signaling pathways (Kim et al., 2016). 
Oxyphenbutazone and phenylbutazone both interacted with HSA via a single hydrogen 
bond with Tyr150. The additional hydroxyl group near the mouth of the pocket possessed 
by oxyphenbutazone leads to a rotation of itself by 180 degrees compared with 
phenylbutazone. The phenolic hydroxyl of oxyphenbutazone interacts with Arg257 and the 
modification F50Y on the interface, highlighted by Mechismo, might have an effect drug 
binding. The phenyl moiety of phenylbutazone also made a hydrogen bond with Arg257 and 
the modification L258V next to it might modify the affinity of drug binding (Ghuman et al., 
2005). The frequencies are about 3.7% in South Asians, and 2.0% and 2.1% in Americans 
and Europeans, and only 0.1% in East Asians. Oxyphenbutazone has been withdrawn in 
three south Asian countries, seven European countries, and the USA. 
4.5 Conclusion and discussion 
Much of the enthusiasm advances in “-omics” have focused on their application to 
understanding human health and diseases. In this chapter, we investigated the distribution of 
single nucleotide polymorphisms in worldwide human population samples measured by 
1000 Genomes Project. Remarkably, some suspicious categories of genes related to 
environmental adaptation, such as those involved in sensory perception functions (e.g., 
odorant and taste receptors) and immunological functions and drug responses (e.g., action 
and toxicity) were found to be significantly enriched for nonsynonymous SNPs, hinting that 
those seem to be targets of human selection processes. Based on the observation that 
nonsynonymous SNPs in the ligand binding domain could change the ligand binding 
affinity to the receptor, we systematically investigated the effects of SNP variations in the 
ligand binding sites on biological processes. Identifying the relationships of genetic 
variations and chemical molecules might provide insights into the mechanisms of how SNPs 
affect sensory perception, diet metabolism, drug response and common diseases, such as 
hypertension, diabetes, and cancer. This study shows the potential of predicting inter-
Chapter IV 
 
87 
individual variability in drug toxicity response by integrating data from multiple datasets. A 
similar prediction was done in an open community challenge, where multiple groups 
developed algorithms for predicting the effects of toxic chemicals on different individuals 
based on genetic profiles and the structural attributes of chemicals (Eduati et al., 2015). 
Though initially promising, improving the accuracy of the predictions would require very 
large sample sizes, because the individual SNPs represented only a small part of overall 
variations in toxic response (Chatterje et al., 2013).  
Nevertheless, pharmacogenetics could provide easier and direct diagnostic applications by 
identifying the association between genotype and drug response, for example, to screen the 
drug with highest efficacy among several candidates or to avoid severe adverse drug 
reactions (Roses, 2002). It is noteworthy that pharmacogenetics prescribing is limited for a 
few drugs due to the problems in identifying replicated associations of phenotype and drug 
reaction, ethical and regulatory considerations (Lauschke 2016). Conquering these problems 
is of crucial importance to further personalize medicine, which could help to deduce 
morbidity and mortality for patients and provide a more rational distribution of health-care 
resources. 
Bringing about the health-care benefits of pharmacogenetics requires a close corporation 
between researchers and clinicians. However, so far only phenotyping for thiopurine 
methyltransferase (TPMT) has been substantially put into the clinical practical to 
prospectively identify TPMT-deficient and heterozygous TPMT patients (Relling et al., 
2011). Approximately 3-14% people of the population have heterozygous TPMT genotype 
and possess low enzyme activity. These patients are likely to experience severe 
myelosuppression with thiopurine drugs treatment, such as azathioprine, and thioguanine 
(Relling et al., 2011). Ideally, researchers and clinicians should be involved together in 
pharmacogenetics research involving patients to boost health-care. 
Overall, our study tested the ability of computational methods to provide understandable 
mechanistic insights about individual differences in sensory perception, diet, and drug 
response by using genetic variation data. Although the suggested methods would require 
further actions to verify, we hope that the analytics presented in this chapter would spark 
interest to other scientists and regulators to explore the data for the benefit of the entire 
community.
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CHAPTER V: General discussion and conclusions 
This dissertation presented a combined systems biology and chemical approach to assess the 
potential toxicities of drugs based on their chemical structures and biological features. The 
proposed framework integrated chemical space and pharmacological space to extract the 
associations of chemical fragments and toxicities, and predicted the potential toxic effects of 
unknown drugs based on the structural alerts (Chapter II). In efforts to offer biological 
interpretability of the outputs of the proposed approach and minimize the false positive of 
the predictions, mechanisms of toxicity have been investigated with gene expression data 
and pathways/networks that were perturbed by toxins (Chapter III). Additionally, the 
relationships of genetic variants and phenotype were extensively analyzed to provide 
insights into how genetic polymorphisms can be related to differences in drug response 
among individuals (Chapter IV). 
5.1 Summary of major findings 
5.1.1 Data-driven identification of structural alerts for predicting drug toxicity 
We developed a workflow that derived chemical substructures/fragments and toxicity 
information from current available public big data sources, and performed statistical 
analyses and machine learning methods to explore the fragment-toxicity relationships, and 
to identify substructures/fragments (structural alerts) that associated with toxic effects. 
Toxicity prediction models, using both traditional SVM and SCCA computational 
approaches, based on those structural alerts showed good overall accuracy in addition to a 
capability to extract associations between chemical fragments and toxicities. Predictions 
conducted for withdrawn drugs confirmed the practicability of the structural alerts dataset 
and computational methods we proposed. Overall, this workflow reduces a large potential 
chemical space to smaller dataset of structural alerts that can be manually curated by human 
experts to provide potentially more accurate and effective toxic predictions for unknown 
compounds. 
5.1.2 Gene expression analysis provided mechanisms of drug toxicity 
Toxicogenomics are valid assays to clarify the molecular pathways involved in drug activity. 
In chapter III, we found that toxicogenomics assays tended to more reflect the mechanism of 
drug action rather than its underlying toxicity. It seemed unanticipated since the target 
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tissues (e.g., liver and kidney) were not traditionally considered as targets of many drugs 
(e.g., acetaminophen). Nevertheless, many known and potentially novel biomarkers are 
evident in the toxicogenomics data, which further validates the power of toxicogenomics. 
Overall, the findings help interpret these toxicity prediction methods, suggesting a necessity 
to include (or exclude) mechanistic contributions to gene expression profiles before 
extracting (for example) multi-gene predictors. Furthermore, we found in vitro gene 
expression arrays were almost always in poor agreement with in vivo equivalents when 
considering data on large set of compounds, which argues for caution in the use of these 
approaches as a replacement for in vivo methods.  
5.1.3 Genetic polymorphisms analysis provided mechanisms of individual differences 
of drug toxicity 
We expanded the use of transcriptomic profiles to genetic profiles to help understand 
mechanisms underlying genetic variation in toxic response on the population level. These 
variants are often found in drug ADME genes, likely often changing the enzymatic activity 
of the gene products, which in turn could result in altered drug toxicity or efficacy. In 
addition, the higher frequency of variants was found in MHC genes, indicated that genetic 
variants could also modulate the risk of immune-mediated toxicity. Moreover, we found 
some chemical compounds containing the same scaffold were in conjunction with specific 
genotype associated with certain susceptibility, e.g., diabetes, suggesting that the combined 
chemical structural and genetic effect may contribute to the underlying risk factors. 
5.2 Contributions and practical implications 
5.2.1 Structural alert concept as applied in drug discovery 
The proposed approach of fragment-based toxicity prediction is thought to be practical at 
different stages of the drug discovery process (and related subjects). At the early stage, the 
structural alert concept would be advisable to screen the drug candidates that could might 
otherwise proceed further to the later stages at great cost. The approach could be also used 
in drug repurposing process to find new indications (i.e., new diseases) for existing drugs by 
detecting their potentially beneficial side effects. A well-known example is thalidomide, 
launched for treating morning sickness and later was withdrawn due to its teratogenicity, but 
then later redeveloped as a treatment for multiple myeloma (Ashburn and Thor, 2004). The 
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structural alerts could also be exploited in fragment-based drug discovery approaches where 
can filter toxicity-related fragments from the chemical space of drug-like molecules 
fragments (Siegel and Vieth, 2007).  
5.2.2 Integrative gene expression-chemical features for toxicity assessment 
Large scale analysis of gene expression profiles is a valuable tool for explaining 
mechanisms for chemotherapeutic drugs and predicting toxicity of unknown compounds. 
Apparently, different compounds generate particular expression profile and similarities of 
expression profiles among compounds can demonstrate similarities of their therapeutic and 
toxic mechanisms. We have found that a systematic approach, combined with information 
on biological and chemical features, is probably required to improve the accuracy of 
predictions of drug toxicity based on expression profiles. The challenge is to connect 
chemical features with biological responses. Our study in Chapter III confirmed the value of 
a chemical-centric perspective of phenotypes to identify the effects of chemicals on 
phenotypic outcomes as mentioned before (Duran et al., 2014) and will help to relate 
chemical features to systemic responses. 
5.2.3 Pharmacogenomic characterization of drug response enables personalized 
medicine 
The integrative genetic and systems biology analysis provides great potential for 
understanding the associations of genetic variants and drug responses (e.g., toxicity) as well 
as for personalization of treatments. The assessment of the changes in protein-ligand affinity 
upon variation may improve our understanding of binding mode and help us to choose more 
efficacious therapeutics. Genetic studies of single nucleotide polymorphisms in various gene 
classes across compounds and across individuals provide a potential strategy for real-world 
applications (e.g., population-specific sensory perception and diet). Chemical structural 
feature/genotype/phenotype can be considered as complementary patient-specific 
parameters to classical factors (e.g., age) to assess their susceptibility to the specific 
treatment response so as to provide clinical decision support to improve patient care. 
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5.3 Limitations and future solutions 
5.3.1 Chemical data limitations and future solutions 
The proposed method of systematically screening structural alerts highly depends on the 
pre-defined chemical fragments and toxicity terms. Future work could test the performance 
with other types of fingerprints and toxicity information. For example, the ECFP4 
fingerprint provided by ChemAxon (http://www.chemaxon.com) as well as chemical 
structure descriptors supplied by commercial software Dragon (https://chm.kode-
solutions.net/products_dragon.php) and toxicity keywords in PharmaPendium 
(https://www.pharmapendium.com/). Another way of getting chemical substructures is by 
directly fragmenting graph structures of chemical compounds into fragments based on the 
recap-rules (Lewell et al., 1998) and the principles of graph theory and depth-first 
algorithms.  
5.3.2 Biological data limitations and future solutions 
The toxicogenomic signatures used in this study were from in vitro, in vivo rodent and in 
vivo human models. The potential limitation is how to bridge species differences and the in 
vivo-in vitro gap in terms of drug efficacy. For that, significant validation is required to 
examine drug ADME processes. Another limitation is that patient-related factors 
contributing to the efficacy of drugs are not currently well understood. To consider these 
individual contributing factors, future work must incorporate larger sample sizes, which 
argues for large, multi-disciplinary national and international collaborations. In parallel, 
GWAS and large-scale genome sequencing data will help to characterize the associations of 
phenotypic outcomes and gene mutations. 
5.3.3 Methodological limitations and future solutions 
Structural alert-based prediction models currently have comparatively poor results when 
predicting toxicities. The best results rely on data normalization, which requires practical 
tests of the methods. The ideal models should integrate all potential mechanisms although 
currently, their performances suffer when predicting multiple toxic endpoints with complex 
mechanisms. Methods are also limited in detecting changes in protein-small molecules 
stability upon a genetic variation. Hence, a universal predictive tool including structure 
signatures related to changes in affinity (e.g determined by modelling the binding sites) 
Chapter V 
 
93 
needs to be developed or improved. 
5.4 Epilogue 
Integrating chemical features with biological features, including gene expression, genetic 
data, and proteomics/metabonomics, is one of the next great challenges faced by 
biomedicine. Our studies assessing chemical toxic outcomes at systems and population 
levels in this thesis will help pave the way for new work on toxicology and disease. 
Methods like those presented in this thesis will be essential in developing new medicines 
and improving diagnostics in the new era of personalized medicine. 
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